<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005411" GROUP_ID="ORAL" ID="853703122910143605" MERGED_FROM="" MODIFIED="2012-08-13 12:57:49 +0100" MODIFIED_BY="Philip Riley" REVIEW_NO="0026" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.2">
<COVER_SHEET MODIFIED="2012-08-13 12:57:49 +0100" MODIFIED_BY="Philip Riley">
<TITLE MODIFIED="2011-11-17 15:43:08 +0000" MODIFIED_BY="[Empty name]">Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)</TITLE>
<CONTACT>
<PERSON ID="06534392732467886944091001154200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brocklehurst</LAST_NAME>
<SUFFIX/>
<POSITION>NIHR Clinician Scientist and Honorary Specialist Registrar in Dental Public Health</POSITION>
<EMAIL_1>paul.brocklehurst@manchester.ac.uk</EMAIL_1>
<EMAIL_2>paul.r.brocklehurst@btopenworld.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-08-13 12:57:49 +0100" MODIFIED_BY="Philip Riley">
<PERSON ID="06534392732467886944091001154200" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brocklehurst</LAST_NAME>
<SUFFIX/>
<POSITION>NIHR Clinician Scientist and Honorary Specialist Registrar in Dental Public Health</POSITION>
<EMAIL_1>paul.brocklehurst@manchester.ac.uk</EMAIL_1>
<EMAIL_2>paul.r.brocklehurst@btopenworld.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15573" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Martin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tickle</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>martin.tickle@northwest.nhs.uk</EMAIL_1>
<EMAIL_2>martin.tickle@manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Oral Health Unit, National Primary Care Research and Development Centre</ADDRESS_1>
<ADDRESS_2>Coupland 3 Building, Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 6782</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 6299</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7514" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Anne-Marie</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Glenny</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Evidence Based Oral Health Care</POSITION>
<EMAIL_1>a.glenny@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7811</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="10777716733626386373101008161445" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Lewis</LAST_NAME>
<SUFFIX/>
<POSITION>Dean, Professor of Oral Medicine</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Dentistry</DEPARTMENT>
<ORGANISATION>Cardiff University</ORGANISATION>
<ADDRESS_1>Heath Park</ADDRESS_1>
<ADDRESS_2/>
<CITY>Cardiff</CITY>
<ZIP>CF14 4XY</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 29 2074 4469</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="49916445860977422984101019161754" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Pemberton</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Oral Medicine</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>Dental Hospital</ADDRESS_1>
<ADDRESS_2>Higher Cambridge Street</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M15 6FH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="55332465735954082094110420141639" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jennifer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Taylor</LAST_NAME>
<SUFFIX/>
<POSITION>Specialist Registrar in Oral Medicine</POSITION>
<EMAIL_1>jennifer.taylor@cmft.nhs.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral Medicine</DEPARTMENT>
<ORGANISATION>University of Manchester</ORGANISATION>
<ADDRESS_1>Dental Hospital</ADDRESS_1>
<ADDRESS_2>Higher Cambridge Street</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M15 6FH</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BE23BD9182E26AA2015807579530F97B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tanya</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Walsh</LAST_NAME>
<SUFFIX/>
<POSITION>Lecturer in Dental Statistics</POSITION>
<EMAIL_1>tanya.walsh@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="EC5E287882E26AA20078D4E698170B92" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Philip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Riley</LAST_NAME>
<SUFFIX/>
<POSITION>Deputy Managing Editor</POSITION>
<EMAIL_1>philip.riley@manchester.ac.uk</EMAIL_1>
<EMAIL_2>philip.riley-2@manchester.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Oral Health Group, School of Dentistry</DEPARTMENT>
<ORGANISATION>The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, 1st Floor, Room 1.006</ADDRESS_1>
<ADDRESS_2>Oxford Road</ADDRESS_2>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 161 275 7818</PHONE_1>
<PHONE_2/>
<FAX_1>+44 161 275 7815</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="74470339575525204814120209111903" MODIFIED="2012-08-13 12:57:49 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Julian</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Yates</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Oral and Maxillofacial Surgery</POSITION>
<EMAIL_1>julian.yates@manchester.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Oral and Maxillofacial Surgery</DEPARTMENT>
<ORGANISATION>School of Dentistry, The University of Manchester</ORGANISATION>
<ADDRESS_1>Coupland III Building, Oxford Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Manchester</CITY>
<ZIP>M13 9PL</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-08-09 11:35:35 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="9" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="9" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-07-04 14:59:06 +0100" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2012-07-04 14:59:06 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-07-04 14:59:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-08-13 10:42:59 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2012-08-13 10:40:31 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-08-13 10:39:58 +0100" MODIFIED_BY="[Empty name]">
<NAME>The University of Manchester</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2012-08-13 10:40:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>MAHSC</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The Cochrane Oral Health Group is supported by the Manchester Academic Health Sciences Centre (MAHSC) and the NIHR Manchester Biomedical Research Centre</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-08-13 10:42:59 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-08-13 10:41:16 +0100" MODIFIED_BY="[Empty name]">
<NAME>Department of Health, Cochrane Incentive Scheme 2010</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Provided GBP 5000 to support this review</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-08-13 10:42:00 +0100" MODIFIED_BY="[Empty name]">
<NAME>New York University (NYU)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>NYU have provided funding for the Cochrane Oral Health Group Global Alliance (<A HREF="http://ohg.cochrane.org/">http://ohg.cochrane.org/</A>)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-08-13 10:42:22 +0100" MODIFIED_BY="[Empty name]">
<NAME>British Orthodontic Society (BOS)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The BOS have provided funding for the Cochrane Oral Health Group Global Alliance (<A HREF="http://ohg.cochrane.org/">http://ohg.cochrane.org/</A>)</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-08-13 10:42:59 +0100" MODIFIED_BY="[Empty name]">
<NAME>British Society of Paediatric Dentistry (BSPD)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The BSPD have provided funding for the Cochrane Oral Health Group Global Alliance (<A HREF="http://ohg.cochrane.org/">http://ohg.cochrane.org/</A>)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-08-13 10:51:18 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-07-04 14:31:12 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-07-04 14:31:12 +0100" MODIFIED_BY="[Empty name]">Systemic interventions for recurrent aphthous stomatitis (mouth ulcers)</TITLE>
<SUMMARY_BODY MODIFIED="2012-07-04 11:52:36 +0100" MODIFIED_BY="[Empty name]">
<P>Mouth ulcers (sores) are one of the most common oral problems and many people suffer with them repeatedly. These can be painful and slow to heal. At its worst, this can cause significant difficulties in eating and drinking. This review found that many different treatments were used to manage this condition, although the evidence of their effectiveness remains inconclusive.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-08-09 11:59:03 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-08-02 21:33:50 +0100" MODIFIED_BY="[Empty name]">
<P>Recurrent aphthous stomatitis (RAS) is the most frequent form of oral ulceration, characterised by recurrent oral mucosal ulceration in an otherwise healthy individual. At its worst RAS can cause significant difficulties in eating and drinking. Treatment is primarily aimed at pain relief and the promotion of healing to reduce the duration of the disease or reduce the rate of recurrence. A variety of topical and systemic therapies have been utilised.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-07-02 16:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the clinical effect of systemic interventions in the reduction of pain associated with RAS, a reduction in episode duration or frequency.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-08-09 11:43:23 +0100" MODIFIED_BY="[Empty name]">
<P>We undertook electronic searches of: Cochrane Oral Health Group and PaPaS Trials Registers (to 6 June 2012); CENTRAL via The Cochrane Library (to Issue 4, 2012); MEDLINE via OVID (1950 to 6 June 2012); EMBASE via OVID (1980 to 6 June 2012); CINAHL via EBSCO (1980 to 6 June 2012); and AMED via PubMed (1950 to 6 June 2012). We searched reference lists from relevant articles and contacted the authors of eligible trials to identify further trials and obtain additional information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-08-09 11:44:31 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) in which the primary outcome measures assess a reduction of pain associated with RAS, a reduction in episode duration or a reduction in episode frequency. Trials were not restricted by outcome alone. We also included RCTs of a cross-over design.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-08-09 11:59:03 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data in duplicate. We contacted trial authors for details of randomisation, blindness and withdrawals. We carried out risk of bias assessment on six domains. We followed The Cochrane Collaboration statistical guidelines and risk ratio (RR) values were to be calculated using fixed-effect models (if two or three trials in each meta-analysis) or random-effects models (if four or more trials in each meta-analysis).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-04 14:58:08 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 25 trials were included, 22 of which were placebo controlled and eight made head-to-head comparisons (five trials had more than two treatment arms). Twenty-one different interventions were assessed. The interventions were grouped into two categories: immunomodulatory/anti-inflammatory and uncertain. Only one study was assessed as being at low risk of bias. There was insufficient evidence to support or refute the use of any intervention.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-08-03 15:33:30 +0100" MODIFIED_BY="[Empty name]">
<P>No single treatment was found to be effective and therefore the results remain inconclusive in regard to the best systemic intervention for RAS. This is likely to reflect the poor methodological rigour of trials, and lack of studies for certain drugs, rather than the true effect of the intervention. It is also recognised that in clinical practice, individual drugs appear to work for individual patients and so the interventions are likely to be complex in nature. In addition, it is acknowledged that systemic interventions are often reserved for those patients who have been unresponsive to topical treatments, and therefore may represent a select group of patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-08-13 10:51:18 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-08-13 10:47:11 +0100" MODIFIED_BY="[Empty name]">
<P>Recurrent aphthous stomatitis (RAS) is the most frequent form of oral ulceration with a prevalence in the general population ranging between 5% and 60% (<LINK REF="REF-Jurge-2006" TYPE="REFERENCE">Jurge 2006</LINK>). It is characterised by recurrent oral mucosal ulceration in an otherwise healthy individual (<LINK REF="REF-Porter-1998" TYPE="REFERENCE">Porter 1998</LINK>). The peak age of onset is between 10 and 19 years of age (<LINK REF="REF-Ship-2000" TYPE="REFERENCE">Ship 2000</LINK>), and it can persist into adulthood and throughout the patient's lifespan, with no gender predilection (<LINK REF="REF-Ship-2000" TYPE="REFERENCE">Ship 2000</LINK>).</P>
<P>According to Bagan (<LINK REF="REF-Bagan-1991" TYPE="REFERENCE">Bagan 1991</LINK>), there are three recognised forms.</P>
<OL>
<LI>Minor aphthae are typically round and less that 10 mm in diameter. These are generally pale in colour with an erythematous border and commonly affect non-keratinised mucosa including the labial and buccal mucosa, the borders of the tongue, and the floor of the mouth. Minor aphthae can occur in isolation but characteristically occur in crops of small numbers. Healing is spontaneous and usually takes 7 to 10 days. Episodes of ulceration are usually followed by an ulcer-free period lasting a few days to several weeks before the next episode occurs (<LINK REF="REF-Thornhill-2007" TYPE="REFERENCE">Thornhill 2007</LINK>). Minor aphthae account for 80% of patients with RAS (<LINK REF="REF-Thornhill-2007" TYPE="REFERENCE">Thornhill 2007</LINK>).</LI>
<LI>Major aphthae are similar to minor aphthae but are larger, usually exceeding 10 mm in diameter. Consequently, healing can take longer (20 to 30 days) and may result in scarring (<LINK REF="REF-Bagan-1991" TYPE="REFERENCE">Bagan 1991</LINK>).</LI>
<LI>Herpetiform ulcers are less than 1 mm in diameter and often occur in multiples from 1 to 100. There is a tendency for adjacent ulcers to merge to form a large affected area. Healing takes place within 15 days (<LINK REF="REF-Bagan-1991" TYPE="REFERENCE">Bagan 1991</LINK>).</LI>
</OL>
<P>The aetiopathogenesis of RAS is multifactoral (<LINK REF="REF-Jurge-2006" TYPE="REFERENCE">Jurge 2006</LINK>). Some patients have a genetic predisposition, with at least 40% of patients having a positive family history (<LINK REF="REF-Sircus-1957" TYPE="REFERENCE">Sircus 1957</LINK>). In a review of the literature, Jurge et al suggests that a bacterial or viral aetiology is unlikely and that the immunopathogenesis of the disease is most likely to involve a cell mediated immune response mechanism involving the generation of T-cells (<LINK REF="REF-Jurge-2006" TYPE="REFERENCE">Jurge 2006</LINK>), interleukins (<LINK REF="REF-Sun-2000" TYPE="REFERENCE">Sun 2000</LINK>), and tumour necrosis factor (TNF) (<LINK REF="REF-Natah-1998" TYPE="REFERENCE">Natah 1998</LINK>). However, a lymphocyte-mediated mechanism in addition to immune complexes have also been proposed (<LINK REF="REF-Jurge-2006" TYPE="REFERENCE">Jurge 2006</LINK>), and cross-reactivity between streptococci and the oral mucosa has been demonstrated (<LINK REF="REF-Lehner-1991" TYPE="REFERENCE">Lehner 1991</LINK>). Local factors can predispose patients to RAS and physical trauma can initiate ulcers in susceptible people (<LINK REF="REF-Wray-1981" TYPE="REFERENCE">Wray 1981</LINK>), but RAS is uncommon in patients who smoke tobacco (<LINK REF="REF-Salonen-1990" TYPE="REFERENCE">Salonen 1990</LINK>). Reduced iron storage has also been reported in 37% of patients (<LINK REF="REF-Porter-1993" TYPE="REFERENCE">Porter 1993</LINK>), and psychological illness has also been postulated but this has not been substantiated (<LINK REF="REF-Miller-1977" TYPE="REFERENCE">Miller 1977</LINK>).</P>
<P>Patients with systemic diseases are also prone to oral ulceration but these manifestations may be secondary to their medical condition and so should be considered separately. These include Behçet's disease, Reiter's syndrome, recurrent erythema multiforme, coeliac disease, Crohn's disease, ulcerative colitis, anaemia and haematinic deficiency (vitamin B12, folic acid and iron).</P>
<P>For clarity, if there is no associated systemic disease, this will be described as 'RAS'. When the ulceration may be associated with an underlying systemic disease, then this will be described as 'RAS type ulceration'.</P>
<SUBSECTION>
<HEADING LEVEL="2">Description of the intervention  </HEADING>
<P>Treatment is primarily aimed at pain relief and the promotion of healing to reduce the duration of the disease or reduce the rate of recurrence. A variety of topical and systemic therapies have been utilised (<LINK REF="REF-Porter-1998" TYPE="REFERENCE">Porter 1998</LINK>), but few studies have demonstrated efficacy. Empirically, effective treatments include the use of corticosteroids, immunosuppressants and topical barriers (<LINK REF="REF-Eisen-2001" TYPE="REFERENCE">Eisen 2001</LINK>). Mycophenolate mofetil, pentoxifylline, colchicine, dapsone and thalidomide have also been used but with some caution due to the potential for adverse effects. Therapies are principally palliative but none result in permanent remission (<LINK REF="REF-Eisen-2001" TYPE="REFERENCE">Eisen 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this review  </HEADING>
<P>All three clinical types of RAS are associated with varying degrees of morbidity, including pain and difficulties in function. At its worst, RAS can cause significant difficulties in eating and drinking, leading to loss of weight. Given its high prevalence, the prevention of RAS or the reduction of the pain or longevity of the disease are important goals in oral medicine.</P>
<P>This review will focus on the use of systemic interventions in the management of RAS and so will complement the planned Cochrane review examining the use of topical agents.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-17 15:01:13 +0000" MODIFIED_BY="[Empty name]">
<P>The objectives of this review are to determine the clinical effectiveness and safety of systemic interventions in the reduction of pain associated with recurrent aphthous stomatitis, a reduction in episode duration or a reduction in episode frequency.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-08-09 16:09:21 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-08-09 15:45:45 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-08-09 14:22:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) in which the primary outcome measures assess a reduction of pain associated with recurrent aphthous stomatitis (RAS), a reduction in episode duration or a reduction in episode frequency. However, trials were not restricted by outcome alone and so other measures were considered if relevant to the review e.g. quality of life or a reduction in morbidity e.g. function. We also included RCTs of a cross-over design, provided that the trial included a suitable washout period and no carry-over effects were evident.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-08-09 14:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>Participants with a previous or current history of recurrent aphthous stomatitis, diagnosed on history and clinical examination. We excluded participants with the following conditions: Behçet's disease, Reiter's syndrome, recurrent erythema multiforme or any viral infection. In addition, patients with coeliac disease, Crohn's disease, ulcerative colitis, anaemia and haematinic deficiency (vitamin B12, folic acid and serum ferritin) were also excluded, when sufficient detail is provided in the trial. This was to ensure that patients entering into a trial are for primary lesions, not lesions that are secondary to a medical condition.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-08-09 14:27:57 +0100" MODIFIED_BY="[Empty name]">
<P>Active treatment included any preventive, palliative or curative interventions administered systemically. Controls were either no active treatment or the administration of a placebo, but head-to-head trials of different interventions were also included, if identified.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-08-09 15:45:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes  </HEADING>
<P>Primary outcome measures assessed were:</P>
<OL>
<LI>pain associated with recurrent aphthous stomatitis;</LI>
<LI>episode duration associated with recurrent aphthous stomatitis;</LI>
<LI>episode frequency associated with recurrent aphthous stomatitis; and</LI>
<LI>safety of the intervention including adverse effects.</LI>
</OL>
<P>Where outcome measurements were taken at multiple time points, the measurements closest to the end of treatment were included in the review. Where cumulative outcome measurements were reported over the total treatment period, these were also included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes  </HEADING>
<P>Secondary outcome measures assessed included any patient reported outcomes that measure improvements in the patients' quality of life and reduction in morbidity (e.g. function).</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-08-09 15:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>For the identification of studies included or considered for this review, detailed search strategies were developed for each database searched. These were based on the search strategy developed for MEDLINE (OVID) but revised appropriately for each database (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). This search strategy was used in addition to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.1.0 [updated March 2011] (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The search of EMBASE was linked to the Cochrane Oral Health Group filter for identifying RCTs.</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches  </HEADING>
<P>The following electronic databases were searched.</P>
<OL>
<LI>The Cochrane Oral Health Group's Trials Register (to 6 June 2012)</LI>
<LI>CENTRAL (The Cochrane Library, 2012, Issue 4)</LI>
<LI>MEDLINE via OVID (1950 to 6 June 2012)</LI>
<LI>EMBASE via OVID (1980 to 6 June 2012)</LI>
<LI>CINAHL (to 6 June 2012)</LI>
<LI>AMED (to 6 June 2012)</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearching</HEADING>
<P>Handsearching for this review was done as part of the Cochrane Worldwide Handsearching Programme (see <A HREF="http://us.cochrane.org/master-list">http://us.cochrane.org/master-list</A>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unpublished trials</HEADING>
<P>We checked the bibliographies of included papers and relevant review articles for studies not identified by the search strategies above. We contacted the authors of identified and included studies to identify unpublished or ongoing trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>Any non-English trials that were identified were translated through The Cochrane Collaboration.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-08-09 16:09:21 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies  </HEADING>
<P>At least two review authors independently scanned the titles and abstracts obtained from the initial electronic searches in duplicate (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We obtained full text reports for the studies that fulfilled the inclusion criteria. When there was insufficient data in the study title to determine whether a study fulfilled the inclusion criteria, we obtained the full text report and at least two review authors independently assessed them in duplicate. Disagreement was resolved by discussion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management  </HEADING>
<P>All studies meeting the inclusion criteria underwent data extraction and an assessment of risk of bias was made using a data extraction form (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). Studies rejected at this and subsequent stages were recorded in the table of excluded studies. At least two review authors independently extracted data from each included study in duplicate using a tool developed for the review. All included trials were discussed in detail by a multidisciplinary team of clinicians, statisticians and methodologists. Differences were resolved by discussion. If a single publication had reported two or more separate studies, then each study would have been data extracted separately. If the findings of a single study had been spread across two or more publications, then the publications would have been extracted as one. For each study with more than one control or comparison group for the intervention, we extracted the results for each intervention arm. For each trial we recorded the following data.</P>
<OL>
<LI>Year of publication, country of origin and source of study funding.</LI>
<LI>Details of the participants including demographic characteristics and criteria for inclusion.</LI>
<LI>Details on the type of intervention and comparisons.</LI>
<LI>Details on the study design.</LI>
<LI>Details on the outcomes reported, including method of assessment and adverse outcomes.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies  </HEADING>
<P>At least two review authors independently assessed the risk of bias of each included study in duplicate using the Cochrane risk of bias assessment tool. The domains that were assessed for each included study were:</P>
<OL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding;</LI>
<LI>completeness of outcome data;</LI>
<LI>risk of selective outcome reporting; and</LI>
<LI>risk of other potential sources of bias.</LI>
</OL>
<P>A description of the domains was tabulated for each included trial, along with a judgement on the risk of bias (low, high or unclear), based on the Cochrane Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The following is an example using the domain 'allocation concealment'.</P>
<OL>
<LI>Low risk of bias - adequate concealment of the allocation (e.g. sequentially numbered, sealed, opaque envelopes or centralised or pharmacy-controlled randomisation).</LI>
<LI>Unclear risk of bias - unclear about whether the allocation was adequately concealed (e.g. where the method of concealment is not described or not described in sufficient detail to allow a definite judgement).</LI>
<LI>High risk of bias - inadequate allocation concealment (e.g. open random number lists or quasi-randomisation such as alternate days, date of birth, or case record number).</LI>
</OL>
<P>A summary assessment of the risk of bias for the primary outcome across the studies was undertaken (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For each study, a summary assessment of risk of bias was provided.</P>
<OL>
<LI>Low risk when there is a low risk of bias across all six key domains.</LI>
<LI>Unclear risk of bias when there is an unclear risk of bias in one or more of the six key domains.</LI>
<LI>High risk of bias when there is a high risk of bias in one or more of the six key domains.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect  </HEADING>
<P>For dichotomous outcomes, the estimate of effect of an intervention was expressed as a risk ratio together with 95% confidence interval (CI), where appropriate. For continuous outcomes, mean difference and 95% CI was used to summarise the data for each group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<P>If cluster randomised trials had been identified and included, analysis was to be undertaken, whenever feasible, at the same level as the randomisation, or at the individual level accounting for the clustering.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data  </HEADING>
<P>We contacted trial authors for missing data if the report was published from the year 2000 or onwards. We considered it unfeasible to obtain data for trials published prior to this cut-off date.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>The significance of any discrepancies in the estimates of the treatment effects from the different trials was to be assessed by means of Cochran's test for heterogeneity, and heterogeneity would be considered significant if P &lt; 0.1 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The I<SUP>2</SUP> statistic, which describes the percentage total variation across studies that is due to heterogeneity rather than chance, was to be used to quantify heterogeneity, with I<SUP>2 </SUP>over 50% being considered substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases  </HEADING>
<P>If there were a sufficient number of trials (more than 10) included in any meta-analysis, publication bias was to be assessed according to the recommendations on testing for funnel plot asymmetry as described in the Cochrane Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis  </HEADING>
<P>Where appropriate, a random-effects meta-analysis was to be applied to the outcomes should there be four or more RCTs included. If fewer than this, a fixed-effect model would have been used to pool the data. Risk ratios were to be combined for dichotomous data, and mean differences for continuous data, if data had allowed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>Had data allowed, sub-group analysis would have been undertaken according to the three classifications of RAS highlighted above: minor, major and herpetiform.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-08-13 10:51:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-08-13 10:47:18 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-08-09 14:43:22 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 1289 studies were identified through the electronic searches (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for flow of studies).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-08-13 10:47:18 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 25 trials were included, 22 of which were placebo controlled and eight made head-to-head comparisons (five trials had more than two treatment arms). The interventions used within the trials were diverse, and the mode of action with regard to the management of recurrent aphthous stomatitis (RAS) often unclear. Interventions can be classified by the known primary mode of action of the therapeutic agent (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). However, for many agents the exact mechanism of action in relation to RAS is unknown. For the purpose of the review, the interventions have been grouped into two categories: immunomodulatory/anti-inflammatory and uncertain (<LINK REF="REF-NMCD-2012" TYPE="REFERENCE">NMCD 2012</LINK>).</P>
<P>In 22 placebo controlled trials, 17 different interventions were assessed (out of a total of 21 interventions included in the review):</P>
<SUBSECTION>
<HEADING LEVEL="4">Immunomodulatory/anti-inflammatory</HEADING>
<UL>
<LI>Beta-glucan (<LINK REF="STD-Koray-2009" TYPE="STUDY">Koray 2009</LINK>)</LI>
<LI>Clofazimine (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>)</LI>
<LI>Colchicine (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>)</LI>
<LI>Levamisole (<LINK REF="STD-De-Cree-1978" TYPE="STUDY">De Cree 1978</LINK>; <LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>; <LINK REF="STD-Weckx-2009" TYPE="STUDY">Weckx 2009</LINK>; <LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>)</LI>
<LI>Montelukast (leukotriene receptor antagonist) (<LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>)</LI>
<LI>Pentoxifylline (<LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>)</LI>
<LI>Prednisone (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>; <LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>)</LI>
<LI>Sulodexide (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Uncertain</HEADING>
<UL>
<LI>Camelthorn (<LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>)</LI>
<LI>Homeopathy (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>)</LI>
<LI>LongoVital (herbal + vitamin) (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>)</LI>
<LI>LongoVital (herbal alone) (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>; <LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>)</LI>
<LI>Propolis (<LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>)</LI>
<LI>Subantimicrobial doxycycline (<LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>)</LI>
<LI>Tetracycline (<LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>)</LI>
<LI>Vitamin B12 (<LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>)</LI>
<LI>Multivitamin (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>)</LI>
</UL>
<P>Eight trials compared active ingredients:</P>
<UL>
<LI>Colchicine versus clofazimine (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>)</LI>
<LI>Colchicine versus prednisolone (<LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>)</LI>
<LI>Prednisone versus montelukast (leukotriene receptor antagonist) (<LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>)</LI>
<LI>Levamisole versus levamisole (different dose) (<LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>)</LI>
<LI>Rofexib versus tinidazole (<LINK REF="STD-Lu-2004" TYPE="STUDY">Lu 2004</LINK>)</LI>
<LI>Sulodexide versus prednisone (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>)</LI>
<LI>LongoVital (herbal + vitamin) versus LongoVital (herbal alone) (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>)</LI>
<LI>Perilla cooking oil verus soybean oil (<LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>)</LI>
</UL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-08-09 14:44:08 +0100" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-08-09 16:53:29 +0100" MODIFIED_BY="[Empty name]">
<P>A summary of the risk of bias for each study is presented in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. One of the 25 included trials was assessed as being at overall low risk of bias (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>). Eight were assessed as being at unclear risk of bias (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>; <LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>; <LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>; <LINK REF="STD-Koray-2009" TYPE="STUDY">Koray 2009</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>). The remainder were assessed as being at overall high risk of bias.</P>
<ALLOCATION MODIFIED="2012-06-27 18:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven of the 25 trials were deemed to be at low risk of bias with regard to sequence generation, but only six of these provided information that allowed a judgement of low risk of bias with regard to allocation concealment (<LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>; <LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>; <LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>). None of the included trials were judged to be at high risk of selection bias, but typically provided insufficient information to make a clear assessment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-08-02 21:46:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fifteen trials were assessed as being at low risk of performance bias, clearly demonstrating blinding of participants/personnel. Only seven were assessed as being at low risk of detection bias (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>; <LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>); one trial was assessed as being at high risk of detection bias as outcome assessment was carried out by investigators unblinded to the treatment groups (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-08-02 22:02:26 +0100" MODIFIED_BY="[Empty name]">
<P>Fourteen trials were assessed as being at low risk of attrition bias (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>; <LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>; <LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>; <LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>; <LINK REF="STD-Koray-2009" TYPE="STUDY">Koray 2009</LINK>; <LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Lu-2004" TYPE="STUDY">Lu 2004</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>; <LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>). Five were assessed as being at high risk of attrition bias (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>; <LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>; <LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-08-09 16:53:24 +0100" MODIFIED_BY="[Empty name]">
<P>Only nine of the included trials were judged to be at low risk of reporting bias (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>; <LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>). Eleven were assessed as being at high risk of bias due to a variety of reasons including: no reporting of important outcomes (e.g. pain), lack of reporting of outcomes listed in the methods section, outcomes reported but not at all listed time points, and measures of variance not reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-08-09 16:53:29 +0100" MODIFIED_BY="[Empty name]">
<P>Nine trials were felt to be at low risk of any other potential biases (<LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>; <LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>; <LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>; <LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>). Six were assessed as being at high risk of bias (<LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>; <LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>) due to reasons including: unclear use of alleviating drugs (e.g. corticosteroids), baseline imbalances in factors such as gender and smoking, and pharmaceutical funding.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-08-13 10:51:18 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Immunomodulatory/anti-inflammatory versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Beta-glucan</HEADING>
<P>One trial randomised 31 participants to receive either 10 mg 1.3 to 1.6 beta-glucan twice per day for 20 days or placebo (<LINK REF="STD-Koray-2009" TYPE="STUDY">Koray 2009</LINK>). The study was at unclear risk of bias. The authors used the ulcer severity score (USS) and report a statistically significant lower mean USS score in the beta-glucan group than in the placebo group (mean difference -4.38; 95% confidence interval (CI) -6.17 to -2.59) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). No data on the individual scale components (number of ulcers, size, duration, ulcer-free period, site and pain).</P>
<P>There was no reporting of adverse effects.</P>
<P>There is insufficient evidence to support or refute the use of beta-glucan for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clofazimine</HEADING>
<P>One trial, assessed as being at high risk of bias, compared clofazimine 100 mg daily for 30 days, then 100 mg every other day (n = 23) with placebo (n = 20) (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>). The authors report that the number of individuals in the clofazimine group who had no further aphthous episodes from beginning treatment until completion of treatment at 6 months was significantly greater than the number in the placebo group (Fisher's exact test P = 0.043) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Within group comparisons comparing periodicity, number, duration and size of lesion from initial evaluation on a monthly basis were also made. No statistically significant differences in pain intensity, patient self-evaluation and physician self-evaluation compared to placebo were observed at 6 months. The number of participants analysed varied across time points and data was not presented in a manner that allowed for further analysis (reported as percentages only).</P>
<P>Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P = 0.015), but these were reported to be easily controlled.</P>
<P>There is insufficient evidence to support or refute the use of clofazimine for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Colchicine</HEADING>
<P>The trial by <LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK> also assessed the effect of colchicine (n = 23) compared to placebo (n = 20). The dose of colchicine was 0.5 mg three times per day.The authors report that the number of individuals in the colchicine group who had no further aphthous episodes after beginning treatment until completion of treatment at 6 months was not significantly different from the number in the placebo group (Fisher's exact test P = 1.000) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Within group comparisons comparing periodicity, number duration and size of lesion from initial evaluation on a monthly basis were also made. No statistically significant differences in pain intensity, patient self-evaluation and physician self-evaluation compared to placebo were observed at 6 months.</P>
<P>However, the authors report that there was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P = 0.009).</P>
<P>There is no evidence to support the use of colchicine for the treatment of RAS and potential evidence of harm at a dose of 1.5 mg per day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Levamisole</HEADING>
<P>Eight trials (seven assessed as being at high risk of bias and one unclear) compared levamisole with placebo (<LINK REF="STD-De-Cree-1978" TYPE="STUDY">De Cree 1978</LINK>; <LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>; <LINK REF="STD-Weckx-2009" TYPE="STUDY">Weckx 2009</LINK>; <LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>). Collectively, the trials did not provide data in a way that allowed for meta-analysis (see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The dose of levamisole was 150 mg per day in all studies, but the duration of treatment varied from 3 consecutive days per episode (with a minimum of 2 weeks between each treatment period) (<LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>), to 11 consecutive days followed by 11 days of no levamisole (for a total of 9 weeks) (<LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>).</P>
<P>There is inconsistent evidence regarding the effectiveness of levamisole. Patients receiving levamisole reported more adverse effects than those receiving placebo, however, no adverse effects are reported as requiring withdrawal of the intervention (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Montelukast (leukotriene receptor antagonist)</HEADING>
<P>One trial assessed as being at unclear risk of bias compared montelukast with placebo (<A HREF="http://archie.cochrane.org/sections/documents/view?document=7F749E7282E26AA2010BFE2C97068703&amp;format=REVMAN#STD-Femiano-2010">Femiano 2010</A>). The trial randomised 40 participants to receive either 10 mg montelukast orally daily for 1 month followed by alternate days for the second month (n = 20) or to placebo (n = 20). Reported outcomes were days to pain cessation and to ulcer healing for the first month of treatment with respect to first ulcer (single episode), and total number of aphthae for each month of treatment and for the 2 months follow-up. Time in days to resolution of first ulcer was shorter for those receiving montelukast (mean difference -3.95; 95% CI -4.38 to -3.52; P &lt; 0.00001) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>); visual analogue scale (VAS) pain mean difference -1.15 (95% CI -1.46 to -0.84; P &lt; 0.00001) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). There was also a significant reduction in the total number of new lesions over the 2-month treatment period (mean difference -3.90; 95% CI -4.55 to -3.25; P &lt; 0.00001) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The study reported equal drug-related adverse effect for those treated with montelukast and placebo.</P>
<P>There is insufficient evidence to support or refute the use of montelukast for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pentoxifylline</HEADING>
<P>A single trial assessed as being at high risk of bias compared pentoxifylline 400 mg 3 times daily (n = 14) with placebo (n = 12) for 60 days with a further 60 day follow-up (<A HREF="http://archie.cochrane.org/sections/documents/view?document=7F749E7282E26AA2010BFE2C97068703&amp;format=REVMAN#STD-Thornhill-2007">Thornhill 2007</A>). No statistically significant differences between the groups were reported for pain, number of ulcers and ulcer-free days at the end of treatment. A statistically significant difference in ulcer size was seen, in favour of pentoxifylline. Data for these outcomes are presented as medians only and are therefore not suitable for meta-analysis. There was no statistically significant difference in the proportion of ulcer-free days compared with pre-treatment status (worse, little improvement, substantial improvement) in either group (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Patients receiving pentoxifylline reported more adverse events than those in the placebo group but this was not statistically significant (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>There is insufficient evidence to support or refute the use of pentoxifylline for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prednisone</HEADING>
<P>Two trials compared prednisone with placebo in trials that were assessed as being at high (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>) and unclear (<LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>) risk of bias. In both trials the dose of oral prednisone commenced at 25 mg with a phased dose reduction over a 2-month period.</P>
<P>
<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK> reports on the number of days to resolution of pain and days to epithelialization of aphthae at 1 month following the start of treatment. Data for these outcomes are presented as ranges only. The trial also reports the number of aphthae per month after the first and second months of therapy; this is reported as the total number of aphthae observed by group, with no estimate of variability. The authors report a statistically significant effect in favour of prednisone.</P>
<P>One significant adverse event (gastritis) was reported for the group receiving prednisone compared to no significant adverse events for the placebo group (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>The second trial to compare prednisone to placebo (<A HREF="http://archie.cochrane.org/sections/documents/view?document=7F749E7282E26AA2010BFE2C97068703&amp;format=REVMAN#STD-Femiano-2010">Femiano 2010</A>) evaluated days to pain cessation and to ulcer healing for the first month of treatment with respect to first ulcer (single episode), and total number of aphthae for each month of treatment and for the 2-months follow-up. Time in days to resolution of first ulcer was shorter for those receiving prednisone (mean difference -6.35; 95% CI -6.74 to -5.96; P &lt; 0.00001) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was also a significant reduction in the total number of new lesions over the 2-month treatment period (mean difference -4.20; 95% CI -4.84 to -3.56; P &lt; 0.00001) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The study reported more drug-related adverse effects for those treated with prednisone than placebo.</P>
<P>There is insufficient evidence to support or refute the use of prednisone for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sulodexide</HEADING>
<P>The trial by (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>) also compared sulodexide (a low-molecular weight product consisting of heparin and dermatan sulphate chains) with placebo. As discussed previously, the trial was at high risk of bias and data was incompletely presented.</P>
<P>Sulodexide was not associated with significant adverse events.</P>
<P>There is insufficient evidence to support or refute the use of sulodexide for the treatment of RAS.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other interventions versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Camel thorn</HEADING>
<P>A single trial of camel thorn randomised 93 participants to the plant distillate (n = 49) or placebo (n = 44) for the aphthous ulcer episode duration (<LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>). The study was assessed as being at unclear risk of bias. The authors report a shorter mean time to complete resolution for camel thorn (mean 4.02 days; range from 3 to 7 days) compared to placebo (mean 8.9 days; range 7 to 14 days), standard deviations not reported. Outcomes of lesion diameter and intensity of pain were analysed at multiple time intervals until 14 days from initial referral. The authors report lower pain and smaller lesions in the camel thorn groups up to 10 days after referral (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>There was no evidence of adverse effects.</P>
<P>There is insufficient evidence to support or refute the use of camel thorn for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Homeopathy</HEADING>
<P>
<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK> undertook a placebo-controlled clinical trial of individualised homeopathy. The trial was assessed as being at high risk of bias. One hundred patients with minor aphthous ulcer were randomised to either a dilution of individualised homeopathic medicines or placebo, in two doses over a 24-hour period and followed up for 6 days. Pain intensity and ulcer size were recorded at baseline, during and at the end of the trial (mornings of days 4 and 6). A statistically significant difference in the number of participants whose ulcers had completely healed by the end of the study was shown, in favour of homeopathy (risk ratio 2.00; 95% CI 1.39 to 2.89; P = 0.0002) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The same findings were shown for 'pain free' by the end of the 6-day study (risk ratio 2.00; 95% CI 1.39 to 2.89). A statistically significant difference was reported in mean pain score and mean ulcer size favouring the homeopathic group (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Summary data are not presented, precluding further analysis.</P>
<P>The authors report that no participant needed to discontinue treatment due to adverse events.</P>
<P>There is insufficient evidence to support or refute the use of homeopathic medicine for the management of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LongoVital (herbal + vitamin)</HEADING>
<P>Forty patients were randomised to receive LongoVital (herbal plus vitamin) or placebo (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>). Outcomes evaluated included the number of ulcer-free days and number of new ulcers over the 4-month treatment period. Data were presented as medians with 95% confidence intervals, so are unsuitable for further analysis. The authors report that there was no statistically significant difference between the groups on these outcomes (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Reported adverse events were minor and evenly distributed between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LongoVital (herbal alone)</HEADING>
<P>Two trials compared LongoVital (herbal alone) with placebo in trials that were assessed as being at high (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>) and unclear (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>) risk of bias. Forty patients were randomised to receive the herbal component of LongoVital alone or placebo (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>). Outcomes evaluated included number of ulcer-free days and number of new ulcers over the 4-month treatment period. Data were presented as medians with 95% confidence intervals, so are unsuitable for further analysis. The authors report that there was no statistically significant difference between the groups on these outcomes (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Reported adverse events were minor and evenly distributed between the groups.</P>
<P>In the second trial, 50 participants were randomised to receive either three tablets of LongoVital (n = 25) or a placebo equivalent (n = 25) (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>). Outcomes reported included the number of days of ulcers, number of days of pain, mean size of ulcers and general degree of discomfort, as a monthly average for the 6-month duration of treatment. There were no statistically significant differences between the groups for these outcomes: mean difference -0.80 (95% CI -3.30 to 1.70; P = 0.53) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>); -3.80 (95% CI -9.39 to 1.79; P = 0.18) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>); -0.30 (95% CI -0.56 to 0.04; P = 0.02) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>); -0.30 (95% CI -0.37 to 0.97; P = 0.38) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
<P>"Very few and mostly harmless side-effects" were observed in the trial.</P>
<P>There is insufficient evidence to support or refute the use of LongoVital for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multivitamin</HEADING>
<P>A single trial at low risk of bias compared a daily multivitamin with placebo in patients who had a validated history of at least three episodes of RAS within the previous 12 months (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>). No statistically significant difference was found between groups with regard to mean number of new lesions (mean difference -0.41; 95% CI -1.85 to 1.03; P = 0.58) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), duration of episodes (mean difference -0.33; 95% CI -2.06 to 1.40; P = 0.71) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), or average mouth pain during RAS episodes (mean difference -0.05; 95% CI -0.71 to 0.61; P = 0.88) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). Similarly, the authors report no statistically significant difference between groups with regard to normalcy of diet or compliance with the interventions.</P>
<P>There is insufficient evidence to support or refute the use of multivitamin for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Propolis</HEADING>
<P>A single trial randomised 19 participants to bee propolis one capsule (500 mg) per day or placebo (<LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>). The trial was assessed as being at high risk of bias. Outcomes included patient reported measurements of the number of new ulcers and the duration and severity of outbreaks over a minimum 6-month period. There was no statistically significant difference in the mean number of lesions in the two groups over the treatment period (mean difference -2.6; 95% CI -7.30 to 2.10), although the authors report a statistically significant difference in the reduction of outbreaks based on the difference between expected number of ulcers and observed number of ulcers (Fisher's exact test one sided P = 0.04). They also report an improvement in quality of life favouring the propolis group based on patients volunteering statements of self-reported improvement (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Propolis was associated with "low rates of minimal side effects".</P>
<P>There is insufficient evidence to support or refute the use of bee propolis for the treatment of RAS. The components of propolis may vary according to geographical area.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subantimicrobial doxycycline</HEADING>
<P>
<LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK> compared subantimicrobial dose doxycycline (SDD) 20 mg twice daily for 90 days (n = 25) with placebo (n = 25). The study was judged as being at high risk of bias. Outcomes measured within the study were number of new ulcers, pain (VAS) and additional ulcer treatment. There was no significant difference in the number of ulcers present at the end of the 90-day treatment period (mean difference -0.5; 95% CI -1.10 to 0.10; P = 0.10) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Cumulative data was also available for the total number of new ulcers over 90 days (mean difference -16.40; 95 CI% -30.44 to -2.36; P = 0.02) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was a statistically significant difference in the number of new lesions per day, with a mean difference -0.19 (95% CI -0.35 to -0.03; P = 0.02) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) in favour of SDD, but not in the mean VAS pain per day (mean difference -5.00; 95% CI -11.93 to 1.93; P = 0.16) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>No differences in adverse events were reported.</P>
<P>There is insufficient evidence to support or refute the use of SDD for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tetracycline</HEADING>
<P>A trial assessed as being at high risk of bias evaluated tetracycline suspension versus placebo. The suspension, containing 250 mg tetracycline, was held in the mouth for 2 minutes and then swallowed, four times per day at new ulcer outbreak, and continued for 20 doses (5 days) (<LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>). No statistically significant difference was found with regard to the average number of new lesions/week (mean difference -0.47; 95% CI -1.34 to 0.40; P = 0.29) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). A statistically significant difference was shown, in favour of tetracycline, for adjusted maximum ulcer size (P = 0.034) and adjusted maximum pain (P = 0.017).</P>
<P>Adverse event rates were comparable between groups.</P>
<P>There is insufficient evidence to support or refute the use of tetracycline for the treatment of RAS.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vitamin B12</HEADING>
<P>A single study, assessed as being at unclear risk of bias, randomised participants to sublingual vitamin B12 (1000 mcg daily for 6 months) or placebo (<LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>). A total of 58 participants were included in the trial. The authors provided additional data for analysis. At completion of treatment at 6 months, compared to placebo the treatment group reported lower pain scores (mean difference -1.72; 95% CI -2.70 to -0.74; P = 0.0006) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>), a shorter average duration of RAS episode (number of days) (mean difference -2.86; 95% CI -5.39 to -0.33; P = 0.03) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and lower frequency of outbreaks per month (mean difference -8.74; 95% CI -16.62 to -0.86; P = 0.03) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). During the last 2 months of treatment, statistically significantly more participants receiving vitamin B12 reached a 'no ulcer' status (risk ratio 3.27; 95% CI 1.23 to 8.66; P = 0.02) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>No adverse events were associated with receiving<SUP> </SUP>vitamin B12 or the placebo in this study.</P>
<P>There is insufficient evidence to support or refute the use of vitamin B12 for the treatment of RAS.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Head-to-head comparisons</HEADING>
<P>Eight trials compared active interventions.</P>
<SUBSECTION>
<HEADING LEVEL="4">Colchicine versus clofazimine</HEADING>
<P>One trial, assessed as being at high risk of bias, compared clofazimine 100 mg daily for 30 days, then 100 mg every other day (n = 23) with colchicine 0.5 mg three times per day (n = 23) (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>). The authors report that the number of individuals in the clofazimine group who had no further aphthous episodes after beginning treatment until completion of treatment at 6 months was significantly greater than the number in the colchicine group (Fisher's exact test P = 0.016). Within group comparisons comparing periodicity, number, duration and size of lesion from initial evaluation on a monthly basis were also made. Statistically significant differences in pain intensity, patient self-evaluation and physician self-evaluation at 6 months were observed in the colchicine group compared to the clofazimine group. The authors report higher pain intensity in the colchicine group, greater physician rated improvement and patient rated satisfaction in the clofazimine group (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The number of participants analysed varied across time points. Data was not presented in a manner that allowed for further analysis.</P>
<P>Clofazimine was associated with an increase in cutaneous adverse effects (Fisher's exact test P = 0.015), but these were reported to be easily controlled. However, the authors report that there was a greater percentage of treatment interruptions in the colchicine group due to gastrointestinal adverse effects (Fisher's exact test P = 0.009)</P>
<P>There is insufficient evidence to support a relative benefit for either colchicine or clofazimine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Colchicine versus prednisolone</HEADING>
<P>
<LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK> randomised participants to 0.5 mg colchicine per day for 3 months (n = 17) or 5 mg prednisolone per day for 3 months (n = 17). The study was judged to be at unclear risk of bias. No statistically significant difference was shown for recurrence during the treatment period (risk ratio 1.30; 95% CI 0.98 to 1.71; P = 0.07) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) or pain at completion of treatment (mean difference -0.16; 95% CI -1.18 to 0.86; P = 0.76) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>) or number of aphthous ulcers at completion (mean difference -0.13; 95% CI -0.50 to 0.24; P = 0.49) (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
<P>Colchicine was associated with statistically significantly more adverse effects than prednisolone with nine participants reporting adverse effects on colchicine and two participants reporting adverse effects on prednisolone.</P>
<P>There is insufficient evidence to support a relative benefit for either colchicine or prednisolone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prednisone versus montelukast (leukotriene receptor antagonist)</HEADING>
<P>One trial (<A HREF="http://archie.cochrane.org/sections/documents/view?document=7F749E7282E26AA2010BFE2C97068703&amp;format=REVMAN#STD-Femiano-2010">Femiano 2010</A>) assessed as unclear risk of bias compared oral prednisone with montelukast, a leukotriene receptor antagonist. Reported outcomes were number of days to pain cessation and to ulcer healing for the first month of treatment with respect to first ulcer (single episode), and total number of aphthae for each month of treatment and for the 2-months follow-up. Time in days to resolution of first ulcer was shorter in favour of montelukast (mean difference -2.40; 95% CI -2.76 to -2.04; P &lt; 0.00001) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). There was no significant reduction in the total number of new lesions over the two month treatment period (mean difference -0.30; 95% CI -0.90 to 0.30; P = 0.33) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>The study reported more drug-related adverse effects for those treated with prednisone than montelukast.</P>
<P>There is insufficient evidence to support a relative benefit for either prednisone or montelukast.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Levamisole versus levamisole (different dosage)</HEADING>
<P>A trial (<LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>) assessed at high risk of bias compared two different doses of levamisole (levamisole 50 mg three times per day for days 1 and 2 compared with levamisole 50 mg three times per day for day 1 and placebo tablet three times per day for day 2). A third group received placebo only. Treatment occurred 2 days per week for 16 weeks. There was some inconsistency in the presentation of the data within the trial. However, the authors report that "All parameters evaluated have been statistically improved in both levamisole groups".</P>
<P>There is insufficient evidence to support a relative benefit for any one particular dose regimen of levamisole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Rofexib versus tinidazole</HEADING>
<P>
<LINK REF="STD-Lu-2004" TYPE="STUDY">Lu 2004</LINK> randomised 60 participants to receive either oral rofecoxib for 4 days (50 mg on first day and 25 to 50 mg per day on the following days) or oral tinidazole (1 g per day for 3 days). The trial was assessed as being at high risk of bias. Summary data for mean pain (VAS) and size of ulcer diameter at end of treatment was presented without standard deviations, preventing further analysis (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The authors report there was no statistically significant difference in total effective rate in the two groups at the end of 4 days (risk ratio 1.17; 95% CI 0.95 to 1.43; P = 0.14) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
<P>There is insufficient evidence to support a relative benefit for either rofecoxib or tinidazole.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sulodexide versus prednisone</HEADING>
<P>A comparison between sulodexide (n = 10) and prednisone (n = 10) was made in a trial assessed as being at high risk of bias (<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>). Data for these outcomes are presented as ranges only with no estimates of variability. The trial also reports the total number of aphthae per month with no estimate of variability precluding further analysis. However, the authors report that the effectiveness of systemic sulodexide was similar to that of systemic prednisone, without significant adverse effects (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>There is insufficient evidence to support a relative benefit for either sulodexide or prednisone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LongoVital (herbal + vitamin) versus LongoVital (herbal alone)</HEADING>
<P>A single trial assessed as being at high risk of bias randomised participants to receive the herbal component of LongoVital alone or LongoVital with herbal plus vitamin component (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>). Outcomes evaluated included the number of ulcer-free days and number of new ulcers over the 4-month treatment period. Data were presented as medians with 95% confidence intervals so unsuitable for further analysis. The authors report that there was no statistically significant difference between the groups on these outcomes (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>Reported adverse events were minor and evenly distributed between the groups (<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>).</P>
<P>There is insufficient evidence to support a relative benefit for either LongoVital (herbal alone) or LongoVital (herbal plus vitamins).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Perilla cooking oil verus soybean oil</HEADING>
<P>Two types of cooking oil were compared in a trial of 33 participants (<LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>). The trial was assessed as being at unclear risk of bias. The treatment phase lasted 8 months and assessed the prevalence of minor RAS, time to resolution, fatty acid/dietary analysis and adverse effects. There was no statistically significant difference in the average number of days for resolution of ulcers over the treatment phase (mean difference 0.80; 95% CI -1.83 to 3.43; P = 0.55) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). No inter-group differences were reported for any other outcome (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Average and monthly prevalence data were presented as figures only so did not allow for further analysis.</P>
<P>No adverse events were reported.</P>
<P>There is insufficient evidence to support a relative benefit for either perilla or soybean cooking oil.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-08-10 17:04:58 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-08-10 14:44:30 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-five randomised controlled trials were included in the review, evaluating the effectiveness of 21 different interventions for the treatment of recurrent aphthous stomatitis (RAS). There was considerable heterogeneity with regard to the comparisons being made within each trial, and the type and timing of outcome assessment. Some trials reported single episodes of ulceration and others multiple episodes (presenting data either cumulatively or per episode). Outcome measures and timing of assessment varied across trials. In most cases, interventions were assessed in single trials. The mode of action by which the intervention was thought to work for the management of RAS not always clear, making grouping of studies difficult. For the purpose of the review, the interventions have been grouped into two broad categories: immunomodulatory/anti-inflammatory and other. Due to heterogeneity and poor reporting in many of the included trials, statistical pooling was not undertaken.</P>
<P>None of the evaluated interventions were shown to be of clear benefit for the treatment of RAS. Statistically significant improvements in outcomes were shown for some interventions, however, given that all trials were judged to be at either high or unclear risk of bias (with the exception of <LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>), it was felt there was insufficient evidence to currently support their use in clinical practice. Further research of these interventions may be warranted: clofazimine, montelukast, prednisone, sulodexide, camel thorn, subantimicrobial doxycycline, vitamin B12.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-08-10 14:46:14 +0100" MODIFIED_BY="[Empty name]">
<P>This review excluded those with ulceration potentially secondary to an underlying medical condition or systemic disease. However, many patients with systemic disease present with RAS type ulceration, for example, Behçet's Disease, Coeliac Disease and vitamin B12 deficiency (<LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK>). All three forms of RAS type ulceration can occur in patients with simple and complex aphthosis, like Behçet's Disease. However, unlike RAS, patients with Behçet's Disease can present with multisystem disease affecting many mucosal surfaces (<LINK REF="REF-Jurge-2006" TYPE="REFERENCE">Jurge 2006</LINK>). The prevalence of RAS type ulceration in patients with coeliac disease lies between 3% to 61% (<LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK>), and this contrasts with a third of the general population (<LINK REF="REF-Kleinman-1994" TYPE="REFERENCE">Kleinman 1994</LINK>). The prevalence of RAS type ulceration in patients with vitamin B12 deficiency ranges from 0 to 42% and studies have found a statistically significant lower daily intake of vitamin B12 in patients that suffer from RAS type ulceration (<LINK REF="REF-Kozlak-2010" TYPE="REFERENCE">Kozlak 2010</LINK>). Given the lack of clarity regarding mode of action of many of the interventions examined in the included trials, the applicability of the review's findings to those with systemic diseases remains unclear.</P>
<P>It is acknowledged that for most people, topical therapies will be the first line of treatment for the management of RAS. A separate review evaluating the effectiveness of topical interventions is being undertaken.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-08-10 15:11:05 +0100" MODIFIED_BY="[Empty name]">
<P>One of the included trials was assessed as being at low risk of bias (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>). Eight trials provided insufficient information to make a clear judgement on risk of bias. The remaining 16 trials were assessed being at high risk of bias for at least one of the assessed domains.</P>
<P>The methodological limitations were extensive and this impacted on the quality of the evidence. Specific issues included clarity with regard to the inclusion/exclusion of participants within the trials, with the definition of RAS not always being apparent. In addition, it was not clear in many of the trials whether individuals with systemic causes of RAS had been excluded from the trial (<LINK REF="STD-De-Cree-1978" TYPE="STUDY">De Cree 1978</LINK>; <LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>; <LINK REF="STD-Weckx-2009" TYPE="STUDY">Weckx 2009</LINK>), which may lead to a difference in the effect estimates when comparing the results of trials where these individuals have and have not been included.</P>
<P>The risk of selection bias with regard to allocation to intervention groups was judged to be low in only six of the included trials (<LINK REF="STD-Femiano-2010" TYPE="STUDY">Femiano 2010</LINK>; <LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>; <LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Pakfetrat-2010" TYPE="STUDY">Pakfetrat 2010</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>), and blind outcome assessment evident in only seven trials (<LINK REF="STD-Lalla-2012" TYPE="STUDY">Lalla 2012</LINK>; <LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>; <LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>; <LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>; <LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>). Given the subjective nature of the outcomes being assessed, this could lead to an important risk of detection bias.</P>
<P>There was an indication of selective outcome reporting in eleven trials. Trials were assessed as being at risk of selective reporting due to the lack of reporting of important outcomes (e.g. pain), lack of reporting of outcomes listed in the methods section, outcomes reported but not at all listed time points, or measures of variance not reported.</P>
<P>Issues regarding lack of accounting for multiplicity following measurement at many time points and reporting at an ulcer level rather than a person level were also apparent, as was analysis within the intervention and comparator groups over time, rather than comparing the groups at a specified time point.</P>
<P>Two trials used the ulcer severity score (USS) (<LINK REF="STD-Koray-2009" TYPE="STUDY">Koray 2009</LINK>; <LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>). This provides a summated score based on categorical scores on a range of clinical domains: number of ulcers, size, duration, ulcer-free period, site and pain. Unless scores for individual components are also provided, it is difficult to interpret the findings as improvement could be due to changes in any one of the domains measured or a composite.   </P>
<P>Some trials reported their outcome measure as a cumulative total at the end of treatment, others provided month-by-month data (<LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>). By not deciding a priori the time point of interest then it is easy for the interpretation to be data driven i.e. by reporting the result according to statistical significance at that time point rather than at the time point which is of clinical interest or importance. One trial combined the data from the run-in and treatment phases (<LINK REF="STD-Bratel-2005" TYPE="STUDY">Bratel 2005</LINK>). The use of arbitrary cut-offs was also found to be a problem in one trial as the difference between severe and moderate improvement was determined by the assessors (<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>).</P>
<P>Many of the trials were small and may have had insufficient participants to determine a statistically significant difference between interventions, or between intervention and control, if in fact this was present.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-08-10 15:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>Changes to the original protocol included splitting the review by mode of administration (i.e. topical, systemic and physical) of the intervention. This was to allow more 'user-friendly' reviews. In addition, an exclusion criteria relating to cross-over studies with an inappropriately short washout period was added to the revised protocol. We recognise that post hoc changes to a protocol may potentially bias the results of a review, however, assessment of eligibility, risk of bias and data extraction was undertaken by at least two members of the review team independently. The results were then discussed across the review team and a consensus reached for each trial. Examining each individual study across a multidisciplinary team meant that all the clinical and methodological issues raised by each trial were discussed thoroughly and openly across the group. Consensus had been reached a priori regarding the types of outcome measures and the timing of the outcome measure (outcome measured nearest to end of treatment), which then determined the selective outcome reporting domain of the risk of bias assessment. This combination of independent and consensual agreement produced a rigorous approach to the assessment process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-08-10 17:04:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK> undertook a systematic review of RAS trials published since 2005. Again, systemic causes of RAS were excluded. In similarity to this review, there was considerable heterogeneity in the types of ulcers that had been included, how results were reported and the interventions used. This was compounded by a lack of study details and how the outcome data were measured. In similarity with this review, <LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK> argued that there was substantial evidence of bias, which reduced the quality of the evidence; the randomisation process was poorly described and loss to follow-up was unclear in many of the included studies. <LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK> also called for future trials to be carefully planned and reported using universal guidelines, for example Consolidated Standards of Reporting Trials (CONSORT; <A HREF="http://www.consort-statement.org/">www.consort-statement.org</A>).</P>
<P>
<LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK> reported both topical and systemic interventions. They found low-dose doxycycline to be effective (<LINK REF="STD-Preshaw-2007" TYPE="STUDY">Preshaw 2007</LINK>; <LINK REF="REF-Skulason-2009" TYPE="REFERENCE">Skulason 2009</LINK>) and minocycline rinses performed better than placebo or tetracycline rinses (<LINK REF="REF-Gorsky-2007" TYPE="REFERENCE">Gorsky 2007</LINK>; <LINK REF="REF-Gorsky-2008" TYPE="REFERENCE">Gorsky 2008</LINK>); although they also raised the issue of the potential for long-term adverse events when patients are treated for extensive periods of time. In similarity to this review, inconsistent results were found with systemic colchicine, the intervention being more efficacious with RAS associated with Behçet's Disease (<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>; <LINK REF="REF-Davatchi-2009" TYPE="REFERENCE">Davatchi 2009</LINK>). Interventions based on plant extracts with anti-inflammatory, analgesic, or antiseptic properties showed some effectiveness as topical treatments (<LINK REF="REF-Amanlou-2007" TYPE="REFERENCE">Amanlou 2007</LINK>; <LINK REF="REF-Babaee-2010" TYPE="REFERENCE">Babaee 2010</LINK>; <LINK REF="REF-de-Armas--2005" TYPE="REFERENCE">de Armas 2005</LINK>; <LINK REF="REF-Martin-2008" TYPE="REFERENCE">Martin 2008</LINK>; <LINK REF="REF-Motallebnejad-2008" TYPE="REFERENCE">Motallebnejad 2008</LINK>).</P>
<P>
<LINK REF="REF-Baccaglini-2011" TYPE="REFERENCE">Baccaglini 2011</LINK> also concluded that the use of vitamin B12 for patients with vitamin B12 deficiency or as an intervention in its own right, was found to be efficacious (<LINK REF="REF-Biedowa-1983" TYPE="REFERENCE">Biedowa 1983</LINK>; <LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>). This concurs with <LINK REF="REF-Carrozzo-2009" TYPE="REFERENCE">Carrozzo 2009</LINK> and the US National Health and Nutrition Examination Survey, where patients with RAS had a statistically significantly lower daily intake of vitamin B12 (<LINK REF="REF-Kozlak-2010" TYPE="REFERENCE">Kozlak 2010</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-08-10 15:46:52 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-08-10 15:22:51 +0100" MODIFIED_BY="[Empty name]">
<P>A wide variety of interventions are currently used for the treatment of recurrent aphthous stomatitis (RAS) in clinical practice, often in a sequential manner, according to the patient's response. In general, systemic interventions are used following ineffective topical therapy.</P>
<P>In this comprehensive systematic review, no single treatment was found to be effective and therefore the results remain inconclusive as regards to the best systemic intervention for RAS. This is likely to reflect the poor methodological rigour of trials, and lack of studies for certain drugs, rather than the true effect of the intervention. It is also recognised that in clinical practice, individual drugs appear to work for individual patients and so the interventions are likely to be complex in nature.</P>
<P>Although comprehensive, this review did not find trials involving several of other systemic interventions used for RAS, for example thalidomide in the absence of any systemic condition, despite its limitations on safety.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-08-10 15:46:52 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical trials in oral medicine have often been compromised due to methodological factors. Careful attention needs to be given to methodological rigour and choice of intervention. Future randomised controlled trials need to ensure they adhere to the CONSORT statement (<A HREF="http://www.consort-statement.org/">www.consort-statement.org</A>) and evaluate interventions that are relevant to current practice and compare them with appropriate controls. Cross-over studies should also be carefully planned to incorporate an adequate washout period. In addition, whilst single treatment interventions are the most common type of trial design, they do not necessarily reflect how the intervention is used within every day practice, which often utilises multiple and/or sequential approaches to treatment. This has the potential to reduce the external validity of the study and so other types of trial design should be considered (e.g. n-of-1 and stepped interventions) at the design stage.</P>
<P>A set of standardised, clinically relevant outcomes measures needs to be developed. This work is underway, registered with COMET (Core Outcome Measures in Effectiveness Trials; <A HREF="http://www.comet-initiative.org/">www.comet-initiative.org</A>), and will be used to inform future reviews and trials in this area.</P>
<P>In addition to examining the effectiveness of interventions, future studies should incorporate an appropriate economic evaluation. This could look at either cost-effectiveness of the intervention or the cost per utility gained.</P>
<P>As it is unclear whether the pathogenesis of RAS is similar or different to that of other RAS type ulceration, this review excluded trials involving patients with relevant associated systemic disease. However, there may be a wealth of good evidence for successful treatment of RAS type ulceration which may be applicable to treatment of RAS. A Cochrane review of systemic treatments for RAS type ulceration in various systemic diseases would be worthwhile.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-08-10 15:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>The authors would like to thank all the previous contributors to the original protocol, particularly Paolo Prolo and Zbys Fedorowicz. The review team would also like to acknowledge Jo Leese, Anne Littlewood and Richard Macey for their assistance in management of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-04-19 12:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>There are no financial conflicts of interest and the authors declare that they do not have any associations with any parties who may have vested interests in the results of this review. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-07-04 15:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>Development of protocol based on the latest Cochrane guidance: Paul Brocklehurst (PRB), Martin Tickle (MT), Mike Lewis (ML), Mike Pemberton (MP), Anne-Marie Glenny (AMG), Jennifer Taylor (JT), Tanya Walsh (TW), Julian Yates (JMY)</P>
<P>Identification of studies: PRB, AMG, JT, Philip Riley (PR), TW</P>
<P>Data extraction: PRB, AMG, JT, PR, TW, JMY</P>
<P>Assessment of risk of bias: PRB, MT, AMG, JT, PR, TW, JMY</P>
<P>Data input/synthesis: PRB, AMG, JT, TW, JMY, PR</P>
<P>Writing of conclusions: PRB, MT, ML, MP, AMG, JT, TW, JMY<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-08-10 15:51:37 +0100" MODIFIED_BY="[Empty name]">
<P>Changes to the original protocol include:</P>
<UL>
<LI>the splitting the review by mode of administration of the intervention (i.e. topical, systemic and physical) in order to produce more 'user-friendly' reviews; and </LI>
<LI>an exclusion criteria relating to cross-over studies with an inappropriately short washout period.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-07-02 16:04:42 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-08-13 10:35:34 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-08-10 17:07:18 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-08-10 17:07:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bratel-2005" MODIFIED="2012-07-04 10:52:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bratel 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-04 10:52:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bratel J, Hakeberg M, Jontell M</AU>
<TI>The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial</TI>
<SO>Oral Health &amp; Preventive Dentistry</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>1</NO>
<PG>3-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Abreu-2009" MODIFIED="2012-08-10 16:16:45 +0100" MODIFIED_BY="[Empty name]" NAME="de Abreu 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-10 16:16:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Abreu MA, Hirata CH, Pimentel DR, Weckx LL</AU>
<TI>Treatment of recurrent aphthous stomatitis with clofazimine</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2009</YR>
<VL>108</VL>
<NO>5</NO>
<PG>714-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Cree-1978" MODIFIED="2012-08-10 16:18:08 +0100" MODIFIED_BY="[Empty name]" NAME="De Cree 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:18:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Cree J, Verhaegen H, De Cock W, Verbruggen F</AU>
<TI>A randomized double-blind trial of levamisole in the therapy of recurrent aphthous stomatitis</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1978</YR>
<VL>45</VL>
<NO>3</NO>
<PG>378-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drinnan-1978" MODIFIED="2012-08-10 16:18:54 +0100" MODIFIED_BY="[Empty name]" NAME="Drinnan 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:18:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DrinnanAJ, Fischman SL</AU>
<TI>Randomized, double-blind study of levamisole in recurrent aphthous stomatitis</TI>
<SO>Journal of Oral Pathology</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>6</NO>
<PG>414-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femiano-2003" MODIFIED="2012-08-10 16:19:46 +0100" MODIFIED_BY="[Empty name]" NAME="Femiano 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-10 16:19:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F, Gombos F, Scully C</AU>
<TI>Recurrent aphthous stomatitis unresponsive to topical corticosteroids: a study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide</TI>
<SO>International Journal of Dermatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>5</NO>
<PG>394-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Femiano-2010" MODIFIED="2012-08-10 16:21:29 +0100" MODIFIED_BY="[Empty name]" NAME="Femiano 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-10 16:21:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Femiano F, Buonaiuto C, Gombos F, Lanza A, Cirillo N</AU>
<TI>Pilot study on recurrent aphthous stomatitis (RAS): a randomized placebo-controlled trial for the comparative therapeutic effects of systemic prednisone and systemic montelukast in subjects unresponsive to topical therapy</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics</SO>
<YR>2010</YR>
<VL>109</VL>
<NO>3</NO>
<PG>402-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graykowski-1978" MODIFIED="2012-08-10 16:22:08 +0100" MODIFIED_BY="[Empty name]" NAME="Graykowski 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:22:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graykowski EA, Kingman A</AU>
<TI>Double-blind trial of tetracycline in recurrent aphthous ulceration</TI>
<SO>Journal of Oral Pathology</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>6</NO>
<PG>376-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamazaki-2006" MODIFIED="2012-08-10 16:23:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hamazaki 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-10 16:23:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamazaki K, Itomura M, Hamazaki T, Sawazaki S</AU>
<TI>Effects of cooking plant oils on recurrent aphthous stomatitis: a randomized, placebo-controlled, double-blind trial</TI>
<SO>Nutrition</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>5</NO>
<PG>534-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolseth-2005" MODIFIED="2012-08-10 16:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kolseth 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-10 16:23:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolseth I, Herlofson BB, Pedersen A</AU>
<TI>Norwegian LongoVital and recurrent aphthous ulceration: a randomized, double-blind, placebo-controlled study</TI>
<SO>Oral Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>6</NO>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koray-2009" MODIFIED="2012-08-10 16:25:12 +0100" MODIFIED_BY="[Empty name]" NAME="Koray 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-10 16:25:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koray M, Ak G, Kürklü E, Tanyeri H, Aydin F, Oguz FS et al</AU>
<TI>The effect of beta-glucan on recurrent aphthous stomatitis</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>111-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lalla-2012" MODIFIED="2012-08-10 16:27:00 +0100" MODIFIED_BY="[Empty name]" NAME="Lalla 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-08-10 16:27:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lalla RV, Choquette LE, Feinn RS, Zawistowski H, Latortue MC, Kelly ET et al</AU>
<TI>Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2012</YR>
<VL>143</VL>
<NO>4</NO>
<PG>370-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2004" MODIFIED="2012-08-10 16:30:22 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-10 16:30:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu DS, Hong YQ, Ma DD</AU>
<TI>Clinical study on the effects of preemptive analgesia on recurrent aphthous ulcers</TI>
<SO>Chinese Journal of Pain Medicine</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>3</NO>
<PG>160-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1977" MODIFIED="2012-08-10 16:36:13 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 1977" YEAR="1977">
<REFERENCE MODIFIED="2012-08-10 16:36:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JD, Degraeve M, Clarysse J, De Loose F, Peremans W</AU>
<TI>Levamisole in aphthous stomatitis: evaluation of three regimens</TI>
<SO>British Medical Journal</SO>
<YR>1977</YR>
<VL>1</VL>
<NO>6062</NO>
<PG>671-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1978" MODIFIED="2012-08-10 16:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:37:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller MF, Silvert ME, Laster LL, Green P, Ship II</AU>
<TI>Effect of levamisole on the incidence and prevalence of recurrent aphthous stomatitis. A double-blind clinical trial</TI>
<SO>Journal of Oral Pathology</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>6</NO>
<PG>387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mousavi-2009" MODIFIED="2012-08-10 16:38:15 +0100" MODIFIED_BY="[Empty name]" NAME="Mousavi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-10 16:38:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mousavi F, Mojaver YN, Asadzadeh M, Mirzazadeh M</AU>
<TI>Homeopathic treatment of minor aphthous ulcer: a randomized, placebo-controlled clinical trial</TI>
<SO>Homeopathy</SO>
<YR>2009</YR>
<VL>98</VL>
<NO>3</NO>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olson-1978" MODIFIED="2012-08-10 16:38:53 +0100" MODIFIED_BY="[Empty name]" NAME="Olson 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:38:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olson JA, Silverman S Jr</AU>
<TI>Double-blind study of levamisole therapy in recurrent aphthous stomatitis</TI>
<SO>Journal of Oral Pathology</SO>
<YR>1978</YR>
<VL>7</VL>
<NO>6</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakfetrat-2010" MODIFIED="2012-08-10 16:40:22 +0100" MODIFIED_BY="[Empty name]" NAME="Pakfetrat 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-10 16:40:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pakfetrat A, Mansourian A, Momen-Heravi F, Delavarian Z, Momen-Beitollahi J, Khalilzadeh O et al</AU>
<TI>Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial</TI>
<SO>Clinical and Investigative Medicine</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>3</NO>
<PG>E189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pourahmad-2010" MODIFIED="2012-08-10 16:41:00 +0100" MODIFIED_BY="[Empty name]" NAME="Pourahmad 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-08-10 16:41:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pourahmad M, Rahiminejad M, Fadaei S, Kashafi H</AU>
<TI>Effects of camel thorn distillate on recurrent oral aphthous lesions</TI>
<SO>Journal der Deutschen Dermatologischen Gesellschaft</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>5</NO>
<PG>348-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Preshaw-2007" MODIFIED="2012-08-10 17:07:18 +0100" MODIFIED_BY="[Empty name]" NAME="Preshaw 2007" YEAR="">
<REFERENCE MODIFIED="2012-08-10 17:07:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preshaw PM, Grainger P, Bradshaw MH, Mohammad AR, Powala CV, Nolan A</AU>
<TI>Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: a pilot study</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>4</NO>
<PG>236-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samet-2007" MODIFIED="2012-08-10 16:43:37 +0100" MODIFIED_BY="[Empty name]" NAME="Samet 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-10 16:43:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samet N, Laurent C, Susarla SM, Samet-Rubinsteen N</AU>
<TI>The effect of bee propolis on recurrent aphthous stomatitis: a pilot study</TI>
<SO>Clinical Oral Investigations</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>2</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thornhill-2007" MODIFIED="2012-08-10 16:44:23 +0100" MODIFIED_BY="[Empty name]" NAME="Thornhill 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-10 16:44:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thornhill MH, Baccaglini L, Theaker E, Pemberton MN</AU>
<TI>A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis</TI>
<SO>Archives of Dermatology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>4</NO>
<PG>463-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-de-Heyning-1978" MODIFIED="2012-08-10 16:45:59 +0100" MODIFIED_BY="[Empty name]" NAME="Van de Heyning 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:45:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van de Heyning J</AU>
<TO>Levamisole in the treatment of recurrent aphthous stomatitis</TO>
<SO>The Laryngoscope</SO>
<YR>1978</YR>
<VL>88</VL>
<NO>3</NO>
<PG>522-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volkov-2009" MODIFIED="2012-08-10 16:47:03 +0100" MODIFIED_BY="[Empty name]" NAME="Volkov 2009" YEAR="">
<REFERENCE MODIFIED="2012-08-10 16:47:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volkov I, Rudoy I, Freud T, Sardal G, Naimer S, Peleg R et al</AU>
<TI>Effectiveness of vitamin B12 in treating recurrent aphthous stomatitis: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Journal of the American Board of Family Medicine</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>1</NO>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weckx-2009" MODIFIED="2012-08-10 16:48:21 +0100" MODIFIED_BY="[Empty name]" NAME="Weckx 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-10 16:48:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weckx LL, Hirata CH, Abreu MA, Fillizolla VC, Silva OM</AU>
<TI>Levamisole does not prevent lesions of recurrent aphthous stomatitis: a double-blind placebo-controlled clinical trial</TI>
<SO>Revista da Associacao Medica Brasileira</SO>
<YR>2009</YR>
<VL>55</VL>
<NO>2</NO>
<PG>132-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zissis-1983" MODIFIED="2012-08-10 16:49:00 +0100" MODIFIED_BY="[Empty name]" NAME="Zissis 1983" YEAR="">
<REFERENCE MODIFIED="2012-08-10 16:49:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zissis NP, Hatzioti AJ, Antoniadis D, Ninika A, Hatziotis JC</AU>
<TI>Therapeutic evaluation of levamisole in recurrent aphthous stomatitis. Double-blind comparison of two dosage schedules of levamisole and placebo</TI>
<SO>Journal of Oral Medicine</SO>
<YR>1983</YR>
<VL>38</VL>
<NO>4</NO>
<PG>161-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-08-10 17:02:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Dolby-1975" MODIFIED="2012-08-10 16:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Dolby 1975" YEAR="1975">
<REFERENCE MODIFIED="2012-08-10 16:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolby AE, Walker DM</AU>
<TI>A trial of cromoglycic acid in recurrent aphthous ulceration</TI>
<SO>The British Journal of Oral Surgery</SO>
<YR>1975</YR>
<VL>12</VL>
<NO>3</NO>
<PG>292-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kowolik-1978" MODIFIED="2012-08-10 16:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Kowolik 1978" YEAR="1978">
<REFERENCE MODIFIED="2012-08-10 16:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kowolik MJ, Muir KF, MacPhee IT</AU>
<TI>Di-sodium cromoglycate in the treatment of recurrent aphthous ulceration</TI>
<SO>British Dental Journal</SO>
<YR>1978</YR>
<VL>144</VL>
<NO>12</NO>
<PG>384-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehner-1976" MODIFIED="2012-08-09 11:13:47 +0100" MODIFIED_BY="[Empty name]" NAME="Lehner 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-08-09 11:13:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehner T, Wilton JM, Ivanyi L</AU>
<TI>Double blind crossover trial of levamisole in recurrent aphthous ulceration</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<NO>7992</NO>
<PG>926-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nolan-1998" MODIFIED="2012-08-10 16:55:24 +0100" MODIFIED_BY="[Empty name]" NAME="Nolan 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-08-10 16:55:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nolan A, Allen E, Badminton J</AU>
<TI>Bio-antioxidant and bio-quinine in the management of recurrent Aphthous Stomatitis</TI>
<SO>Journal of Dental Research</SO>
<YR>1998</YR>
<VL>77</VL>
<PG>895</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1990a" MODIFIED="2012-08-09 10:37:30 +0100" MODIFIED_BY="[Empty name]" NAME="Pedersen 1990a" YEAR="1990">
<REFERENCE MODIFIED="2012-08-09 10:37:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen A, Hougen HP, Klausen B, Winther K</AU>
<TI>LongoVital in the prevention of recurrent aphthous ulceration</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>8</NO>
<PG>371-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1990b" MODIFIED="2012-08-09 11:10:48 +0100" MODIFIED_BY="[Empty name]" NAME="Pedersen 1990b" YEAR="1990">
<REFERENCE MODIFIED="2012-08-09 11:10:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen A, Klausen B, Hougen HP, Ryder L, Winther K</AU>
<TI>Immunomodulation by LongoVital in patients with recurrent aphthous ulceration</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>8</NO>
<PG>376-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raeste-1981" MODIFIED="2012-08-10 17:01:31 +0100" MODIFIED_BY="[Empty name]" NAME="Raeste 1981" YEAR="1981">
<REFERENCE MODIFIED="2012-08-10 17:01:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raeste AM, Ranta H, Ahtiainen EM, Jarvinen J, Tuompo H</AU>
<TI>Oral administration of zinc sulphate in the treatment of recurrent aphthous stomatitis</TI>
<SO>Journal of Dental Research</SO>
<YR>1981</YR>
<VL>60</VL>
<PG>1248</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharquie-2008" MODIFIED="2012-08-10 17:02:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sharquie 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-10 17:02:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharquie KE, Najim RA, Al-Hayani RK, Al-Nuaimy AA, Maroof DM</AU>
<TI>The therapeutic and prophylactic role of oral zinc sulfate in management of recurrent aphthous stomatitis (ras) in comparison with dapsone</TI>
<SO>Saudi Medical Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>5</NO>
<PG>734-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2009" MODIFIED="2012-07-04 15:21:46 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-07-04 15:21:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang TY, Jang TY</AU>
<TI>The value of local botulinum toxin A injection in the treatment of the pain of aphthous ulcer</TI>
<SO>European Archives of Oto-rhino-laryngology</SO>
<YR>2009</YR>
<VL>266</VL>
<NO>3</NO>
<PG>445-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-08-13 10:35:34 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-08-13 10:35:34 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amanlou-2007" MODIFIED="2012-08-10 17:03:21 +0100" MODIFIED_BY="[Empty name]" NAME="Amanlou 2007" TYPE="JOURNAL_ARTICLE">
<AU>Amanlou M, Babaee N, Saheb-Jamee M, Salehnia A, Farsam H, Tohidast Akrad Z</AU>
<TI>Efficacy of Satureja khuzistanica extract and its essential oil preparations in the management of recurrent aphthous stomatitis</TI>
<SO>Daru</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>4</NO>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babaee-2010" MODIFIED="2012-08-10 17:05:08 +0100" MODIFIED_BY="[Empty name]" NAME="Babaee 2010" TYPE="JOURNAL_ARTICLE">
<AU>Babaee N, Mansourian A, Momen-Heravi F, Moghadamnia A, Momen-Beitollahi J</AU>
<TI>The efficacy of a paste containing Myrtus communis (Myrtle) in the management of recurrent aphthous stomatitis:a randomized controlled trial</TI>
<SO>Clinical Oral Investigations</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>1</NO>
<PG>65-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baccaglini-2011" MODIFIED="2012-08-10 17:06:06 +0100" MODIFIED_BY="[Empty name]" NAME="Baccaglini 2011" TYPE="JOURNAL_ARTICLE">
<AU>Baccaglini L, Lalla RV, Bruce AJ, Sartori-Valinotti JC, Latortue MC, Carrozzo M et al</AU>
<TI>Urban legends: recurrent aphthous stomatitis</TI>
<SO>Oral Diseases</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>8</NO>
<PG>755-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagan-1991" MODIFIED="2012-08-10 17:06:31 +0100" MODIFIED_BY="[Empty name]" NAME="Bagan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Bagan JV, Sanchis JM, Milan MA, Penarrocha M, Silvestre FJ</AU>
<TI>Recurrent aphthous stomatitis: a study of the clinical characteristics of lesions in 93 cases</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>8</NO>
<PG>395-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bazrafshani-2002" MODIFIED="2012-08-13 09:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Bazrafshani 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bazrafshani MR, Hajeer AH, Ollier WE, Thornhill MH</AU>
<TI>IL-1B and IL-6 gene polymorphisms encode significant risk for the development of recurrent aphthous stomatitis (RAS)</TI>
<SO>Genes and Immunity</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>5</NO>
<PG>302-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biedowa-1983" MODIFIED="2012-08-10 17:08:39 +0100" MODIFIED_BY="[Empty name]" NAME="Biedowa 1983" TYPE="JOURNAL_ARTICLE">
<AU>Biedowa J, Knychalska-Karwan Z</AU>
<TI>Submucous injections of vitamin B12 and hydrocortisone in cases of recurrent aphthae</TI>
<SO>Czasopismo stomatologiczne</SO>
<YR>1983</YR>
<VL>36</VL>
<NO>7</NO>
<PG>565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carrozzo-2009" MODIFIED="2012-08-13 09:59:30 +0100" MODIFIED_BY="[Empty name]" NAME="Carrozzo 2009" TYPE="JOURNAL_ARTICLE">
<AU>Carrozzo M</AU>
<TI>Vitamin B12 for the treatment of recurrent aphthous stomatitis</TI>
<SO>Evidence-Based Dentistry</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>114-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davatchi-2009" MODIFIED="2012-08-13 10:01:08 +0100" MODIFIED_BY="[Empty name]" NAME="Davatchi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H et al</AU>
<TI>Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial</TI>
<SO>Modern Rheumatology</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>5</NO>
<PG>542-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Armas--2005" MODIFIED="2012-08-13 10:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="de Armas  2005" TYPE="JOURNAL_ARTICLE">
<AU>de Armas E, Sarracent Y, Marrero E, Fernández O, Branford-White C</AU>
<TI>Efficacy of Rhizophora mangle aqueous bark extract (RMABE) in the treatment of aphthous ulcers: a pilot study</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1711-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eisen-2001" MODIFIED="2012-08-13 10:03:16 +0100" MODIFIED_BY="[Empty name]" NAME="Eisen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Eisen D, Lynch DP</AU>
<TI>Selecting topical and systemic agents for recurrent aphthous stomatitis</TI>
<SO>Cutis</SO>
<YR>2001</YR>
<VL>68</VL>
<NO>3</NO>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorsky-2007" MODIFIED="2012-08-13 10:04:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gorsky 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N</AU>
<TI>Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study</TI>
<SO>Dermatology Online Journal</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>2</NO>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gorsky-2008" MODIFIED="2012-07-03 14:20:35 +0100" MODIFIED_BY="[Empty name]" NAME="Gorsky 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gorsky M, Epstein J, Raviv A, Yaniv R, Truelove E</AU>
<TI>Topical minocycline for managing symptoms of recurrent aphthous stomatitis</TI>
<SO>Special Care in Dentistry</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-09 14:30:19 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jurge-2006" MODIFIED="2012-08-13 10:06:03 +0100" MODIFIED_BY="[Empty name]" NAME="Jurge 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jurge S, Kuffer R, Scully C, Porter SR</AU>
<TI>Mucosal disease series. Number VI. Recurrent aphthous stomatitis</TI>
<SO>Oral Diseases</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>1-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleinman-1994" MODIFIED="2012-08-13 10:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="Kleinman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kleinman DV, Swango PA, Pindborg JJ</AU>
<TI>Epidemiology of oral mucosal lesions in United States schoolchildren: 1986&#8211;87</TI>
<SO>Community Dentistry and Oral Epidemiology</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>4</NO>
<PG>243-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kozlak-2010" MODIFIED="2012-08-13 10:08:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kozlak 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kozlak ST, Walsh SJ, Lalla RV</AU>
<TI>Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>5</NO>
<PG>420-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehner-1991" MODIFIED="2012-08-13 10:10:08 +0100" MODIFIED_BY="[Empty name]" NAME="Lehner 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T</AU>
<TI>Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet's syndrome</TI>
<SO>Infection and Immunity</SO>
<YR>1991</YR>
<VL>59</VL>
<NO>4</NO>
<PG>1434-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-2008" MODIFIED="2012-08-13 10:11:38 +0100" MODIFIED_BY="[Empty name]" NAME="Martin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Martin MD, Sherman J, van der Ven P, Burgess J</AU>
<TI>A controlled trial of a dissolving oral patch concerning glycyrrhiza (licorice) herbal extract for the treatment of aphthous ulcers</TI>
<SO>General Dentistry</SO>
<YR>2008</YR>
<VL>56</VL>
<NO>2</NO>
<PG>206-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-2012" MODIFIED="2012-07-04 11:24:10 +0100" MODIFIED_BY="[Empty name]" NAME="Martindale 2012" TYPE="OTHER">
<AU>Martindale</AU>
<TI>The Complete Drug Reference</TI>
<SO>http://www.medicinescomplete.com/mc/martindale/current/</SO>
<YR>(accessed via MedicinesComplete May 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1977" MODIFIED="2012-08-13 10:12:46 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1977" TYPE="JOURNAL_ARTICLE">
<AU>Miller MF, Ship II</AU>
<TI>A retrospective study of the prevalence and incidence of recurrent aphthous ulcers in a professional population, 1958-1971</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1977</YR>
<VL>43</VL>
<NO>4</NO>
<PG>532-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Motallebnejad-2008" MODIFIED="2012-07-03 15:06:19 +0100" MODIFIED_BY="[Empty name]" NAME="Motallebnejad 2008" TYPE="JOURNAL_ARTICLE">
<AU>Motallebnejad M, Moghadamnia A, Talei M</AU>
<TI>The efficacy of Hypericum perforatum extract on recurrent aphthous ulcers</TI>
<SO>Journal of Medical Sciences</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>39-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Natah-1998" MODIFIED="2012-08-13 10:17:36 +0100" MODIFIED_BY="[Empty name]" NAME="Natah 1998" TYPE="JOURNAL_ARTICLE">
<AU>Natah SS, Häyrinen-Immonen R, Hietanen J, Malmström M, Konttinen YT</AU>
<TI>Quantitative assessment of mast cells in recurrent aphthous ulcers (RAU)</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>3</NO>
<PG>124-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NMCD-2012" MODIFIED="2012-07-04 11:37:01 +0100" MODIFIED_BY="[Empty name]" NAME="NMCD 2012" TYPE="OTHER">
<AU>Natural Medicines Comprehensive Database</AU>
<SO>http://naturaldatabase.therapeuticresearch.com/home.aspx</SO>
<YR>(accessed May 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1993" MODIFIED="2012-08-13 10:18:42 +0100" MODIFIED_BY="[Empty name]" NAME="Porter 1993" TYPE="JOURNAL_ARTICLE">
<AU>Porter SR, Kingsmill V, Scully C</AU>
<TI>Audit of diagnosis and investigations in patients with recurrent aphthous stomatitis</TI>
<SO>Oral Surgery, Oral Medicine, and Oral Pathology</SO>
<YR>1993</YR>
<VL>76</VL>
<NO>4</NO>
<PG>449-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1998" MODIFIED="2012-08-13 10:19:39 +0100" MODIFIED_BY="[Empty name]" NAME="Porter 1998" TYPE="JOURNAL_ARTICLE">
<AU>Porter SR, Scully C, Pedersen A</AU>
<TI>Recurrent aphthous stomatitis</TI>
<SO>Critical Reviews in Oral Biology and Medicine</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>3</NO>
<PG>306-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salonen-1990" MODIFIED="2012-08-13 10:21:40 +0100" MODIFIED_BY="[Empty name]" NAME="Salonen 1990" TYPE="JOURNAL_ARTICLE">
<AU>Salonen L, Axéll T, Helldén L</AU>
<TI>Occurrence of oral mucosal lesions, the influence of tobacco habits and an estimate of treatment time in an adult Swedish population</TI>
<SO>Journal of Oral Pathology and Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>4</NO>
<PG>170-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ship-2000" MODIFIED="2012-08-13 10:24:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ship 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ship JA, Chavez EM, Doerr PA, Henson BS, Sarmadi M</AU>
<TI>Recurrent aphthous stomatitis</TI>
<SO>Quintessence International</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>2</NO>
<PG>95-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sircus-1957" MODIFIED="2012-08-13 10:25:21 +0100" MODIFIED_BY="[Empty name]" NAME="Sircus 1957" TYPE="JOURNAL_ARTICLE">
<AU>Sircus W, Church R, Kelleher J</AU>
<TI>Recurrent aphthous ulceration of the mouth; a study of the natural history, aetiology, and treatment</TI>
<SO>The Quarterly Journal of Medicine</SO>
<YR>1957</YR>
<VL>26</VL>
<NO>102</NO>
<PG>235-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skulason-2009" MODIFIED="2012-08-13 10:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Skulason 2009" TYPE="JOURNAL_ARTICLE">
<AU>Skulason S, Holbrook WP, Kristmundsdottir T</AU>
<TI>Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous ulcers</TI>
<SO>Acta Odontologica Scandinavica</SO>
<YR>2009</YR>
<VL>67</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2000" MODIFIED="2012-08-13 10:30:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sun A, Chu CT, Liu BY, Wang JT, Leu JS, Chiang CP</AU>
<TI>Expression of interleukin-2 receptor by activated peripheral blood lymphocytes upregulated by the plasma level of interleukin-2 in patients with recurrent aphthous ulcers</TI>
<SO>Proceedings of the National Science Council, Republic of China. Part B, Life Sciences</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>3</NO>
<PG>116-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornhill-2007" MODIFIED="2012-08-13 10:33:14 +0100" MODIFIED_BY="[Empty name]" NAME="Thornhill 2007" TYPE="JOURNAL_ARTICLE">
<AU>Thornhill MH, Baccaglini L, Theaker E, Pemberton MN</AU>
<TI>A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis</TI>
<SO>Archives of Dermatology</SO>
<YR>2007</YR>
<VL>143</VL>
<NO>4</NO>
<PG>463-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wray-1981" MODIFIED="2012-08-13 10:35:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wray 1981" TYPE="JOURNAL_ARTICLE">
<AU>Wray D, Graykowski EA, Notkins AL</AU>
<TI>Role of mucosal injury in initiating recurrent aphthous stomatitis</TI>
<SO>British Medical Journal</SO>
<YR>1981</YR>
<VL>283</VL>
<NO>6306</NO>
<PG>1569-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-08-13 10:53:32 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-08-13 10:53:32 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-08-10 15:53:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bratel-2005">
<CHAR_METHODS MODIFIED="2012-03-13 13:59:21 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Göteburg, Sweden</P>
<P>Number of centres: 1</P>
<P>Funding: supported by Paramedical A/S Denmark</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-22 12:23:48 +0000" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Clinic of Oral Medicine, Public Dental Service of Göteburg, Sweden</P>
<P>Age: mean 43.2 years (range = 21 to 68) in LongoVital group; mean 40.4 years (range = 21 to 54) in placebo group</P>
<P>Gender: 28 females/22 males (16 females/9 males in LongoVital group; 12 females/13 males in placebo group)</P>
<P>Inclusion criteria: at least 30 days of ulcers or at least 3 periods of RAS recurrences during phase 1</P>
<P>Exclusion criteria: not stated</P>
<P>Number randomised: 50</P>
<P>Number analysed: 50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:52:43 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: LongoVital versus placebo</P>
<P>Gr A (n = 25): LongoVital herbal tablets 3 times per day for 6 months</P>
<P>Gr B (n = 25): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-14 12:17:43 +0000" MODIFIED_BY="[Empty name]">
<P>Ulcer duration, pain, number, size. Blood analyses (CD4+, CD8+ and CD3+ T cells, S-Asat, S-Alat, S-ALP and S-gamma GT)<BR/>
</P>
<P> </P>
<P>Duration of follow-up: 6 months treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:53:56 +0100" MODIFIED_BY="[Empty name]">
<P>Pre treatment phase 3 months then treatment phase of 6 months. Reported outcomes at 9 months (end of treatment). Data presented as monthly average for pre-treatment and treatment period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:54:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Abreu-2009">
<CHAR_METHODS MODIFIED="2012-03-13 14:02:53 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: São Paulo, Brazil</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-27 16:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Stomatology Outclinic, Federal University of São Paulo, Brazil</P>
<P>Age: range = 15 to 60 years; mean 38 years (SD 2.4) in clofazimine group; mean 34 years (SD 2.6) in colchicine group; mean 45 years (SD 3.4) in placebo group</P>
<P>Gender: 68% males</P>
<P>Inclusion criteria: aphthous stomatitis episodes associated with intense pain (constant pain and difficulty eating and speaking); no response to topical therapies</P>
<P>Exclusion criteria: hypersensitivity to clofazimine or colchicine; cardiac, renal, hepatic, hematologic, and gastrointestinal abnormalities or evidence of underlying systemic diseases such as connective tissue diseases, malignant neoplasias, and infections (e.g. HIV); pregnant and lactating women; use of medications which may interact with colchicine (e.g. depressors of bone marrow and central nervous system, sympathomimetics, acidifying or alkalizing agents, and NSAIDs) or with clofazimine (e.g. dapsone, rifampicin, estrogens, and vitamin A); use of medications which may cause a beneficial action on the lesions (e.g. corticosteroids, thalidomide, levamisole, pentoxifylline, or any immunomodulatory agent)</P>
<P>Number randomised: 66</P>
<P>Number analysed: varies across outcomes and time points</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:53:03 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: clofazimine versus colchicine versus placebo</P>
<P> </P>
<P>Gr A (n = 23): clofazimine 100 mg daily for 30 days, then 100 mg every other day</P>
<P>Gr B (n = 23): colchicine 0.5 mg 3 times per day<BR/>Gr C (n = 20): placebo pill twice per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 15:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer number, size, duration, pain intensity; time since last episode (frequency); patient satisfaction; physician rated improvement; adverse events</P>
<P> </P>
<P>Duration of follow-up: 6 months treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>80% of the study sample presented with minor clinical form, 12% with major form, and 8% with herpetiform</P>
<P>Data presented as percentages. Number analysed per group at each time point due to exclusions from analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:53:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Cree-1978">
<CHAR_METHODS MODIFIED="2012-03-13 15:51:54 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Antwerp, Belgium</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-02 12:12:17 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Clinical Research Unit, St Bartholomeus</P>
<P>Age: median 25 years (range = 14 to 72) in levamisole group; median 30 years (range = 14 to 74) in placebo group</P>
<P>Gender: 13 females/5 males (6 females/3 males in levamisole group; 7 females/2 males in placebo group)</P>
<P>Inclusion criteria: history of at least 1 aphthous lesion per month during the preceding year</P>
<P>Exclusion criteria: not stated</P>
<P>Number randomised: 18</P>
<P>Number analysed: 18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:53:16 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 9): 50 mg levamisole tablet (patients received coded vial containing 27 tablets and, when a RAS episode began, took 1 tablet 3 times per day for 3 consecutive days, provided at least 2 weeks had elapsed since the previous drug period. Therefore there was enough medication to allow evaluation of 3 treatment episodes per patient. No patient received any concurrent medications</P>
<P>Gr B (n = 9): placebo as for Gr A (all tablets identical in appearance)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-27 16:55:59 +0100" MODIFIED_BY="[Empty name]">
<P>Median time interval between treatment periods (frequency); median duration of aphthous episodes; pain</P>
<P> </P>
<P>Duration of follow-up: "Total duration of the study period to cross-over (that is, the median time required for three RAS episodes to occur) was 95 (49 to 46 1) days for the levamisole group and 50 (45 to 75) days for the placebo group" </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:55:42 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion of participants with systemic disease not explicit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-13 10:52:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drinnan-1978">
<CHAR_METHODS MODIFIED="2012-03-14 09:12:19 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Buffalo, USA</P>
<P>Number of centres: 1</P>
<P>Funding: supported by Janssen R &amp; D, Inc, New Jersey, USA</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-14 09:57:57 +0000" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients were either under the care of one of the clinical investigators or were referred by their physicians or dentists to the Department of Oral Medicine of the School of Dentistry at the State University of New York at Buffalo specifically for the study</P>
<P>Age: range = 9 to 65</P>
<P>Gender: 19 females/11 males</P>
<P>Inclusion criteria: documented history of at least 3 previous episodes of RAS; normally experienced at least 6 episodes during a 12-month period; able to take tablets</P>
<P>Exclusion criteria: pregnant; suffering from any chronic debilitating disease; receiving antibiotic or steroid medication; suffered from continuous or persistent oral ulcerations i.e. were "never free" of ulcers</P>
<P>Number randomised: 30</P>
<P>Number analysed: 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-13 10:52:10 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 11): 150 mg levamisole to be taken daily for 3 days at onset of first prodromal symptoms of an ulcer (total of 450 mg per 3-day period) *, **</P>
<P>Gr B (n = 13): placebo as for Gr A</P>
<P>* Dose adjusted to not exceed 2.5 mg/kg per day for those weighing less than 70 kg</P>
<P>** Medication was not to be repeated within 1 week and a second 3-day course was only to be started for a newly developing ulcer</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-02 12:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer number and duration; interval between episodes (frequency); pain; adverse events</P>
<P> </P>
<P>Duration of follow-up: follow-up dependant on when patients took medication</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:55:10 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:54:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Femiano-2003">
<CHAR_METHODS MODIFIED="2012-03-14 10:56:09 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Naples, Italy</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-14 11:56:42 +0000" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Stomatology Clinic, School of Medicine and Surgery, II University of Naples, Italy</P>
<P>Age: median 32 years; range = 21 to 48</P>
<P>Gender: 24 females/6 males</P>
<P>Inclusion criteria: frequent minor RAS over more than 4 months; at least 3 episodes of aphthae each month; no abnormal findings on investigation; failed to respond to conventional topical therapies (usually corticosteroids)</P>
<P>Exclusion criteria: not stated</P>
<P>Number randomised: 30</P>
<P>Number analysed: 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: sulodexide versus prednisone versus placebo</P>
<P>Gr A (n = 10): sulodexide ULS 250 orally twice per day for 1 month, then once per day for 1 month</P>
<P>Gr B (n = 10): oral prednisone 25 mg in the morning for 1 week, then dose reduction as follows: 20 mg in weeks 2 and 3; 15 mg in weeks 4 and 5; 10 mg in weeks 6 and 7; 5 mg in week 8</P>
<P>Gr C (n = 10): placebo (cellulose starch 100 mg) as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-14 16:48:48 +0000" MODIFIED_BY="[Empty name]">
<P>Days to pain cessation (patient assessed VAS); days to ulcer epithelialization (patient assessed); number of new aphthae; adverse events (recorded by patient) </P>
<P> </P>
<P>Duration of follow-up: 4 months (2 months treatment, 2 months follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>Reported at ulcer level with no estimate of variability. Also authors report p values for t-tests despite three arm trial. Not clear which comparisons are being referred to with the p value results</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:54:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Femiano-2010">
<CHAR_METHODS MODIFIED="2012-03-14 16:55:05 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Naples, Italy</P>
<P>Number of centres: 1 </P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-02 12:11:39 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Stomatology Clinic, School of Medicine and Surgery, II University of Naples, Italy</P>
<P>Age: median 26 years; range = 18 to 48</P>
<P>Gender: 38 females/22 males (10 females/10 males in prednisone group; 12 females/8 males in montelukast group)</P>
<P>Inclusion criteria: history of RAS for minimum 6 months with average of 2 outbreaks per month and 2 to 3 aphthae per outbreak; previous reporting in patient's clinical history of oral pain and discomfort during outbreaks; unresponsive to topical betamethasone dipropionate ointment therapy used for 2 weeks or difficulty applying topical ointment</P>
<P>Exclusion criteria: altered hematological parameters; gastrointestinal diseases; endocrine system disorders; local oral factors which could favour the appearance of aphthae; other medications taken usually or occasionally (NSAIDS, activators of adenosine triphosphate-sensitive potassium [nicorandil], angiotensin-converting enzyme inhibitors, and antiarrhythmics)</P>
<P>Number randomised: 60</P>
<P>Number analysed: unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:54:32 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: prednisone versus montelukast (leukotriene receptor antagonist) versus placebo</P>
<P> </P>
<P>Gr A (n = 20): oral prednisone 25 mg per day for 15 days, then 12.5 mg per day for 15 days, then 6.25 mg per day for 15 days, then 6.25 mg on alternate days for 15 days</P>
<P>Gr B (n = 20): oral montelukast 10 mg every evening for first month and then on alternate days for the second month</P>
<P>Gr C (n = 20): placebo (cellulose) 100 mg every day for first month and then on alternate days for the second month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:43:31 +0000" MODIFIED_BY="[Empty name]">
<P>Number of lesions per month; pain;efficacy on time to resolution; adverse events</P>
<P> </P>
<P>Duration of follow-up: 4 months (2 months treatment, 2 months follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:54:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-13 10:52:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graykowski-1978">
<CHAR_METHODS MODIFIED="2012-03-22 12:56:03 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Bethesda, USA</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-22 13:24:05 +0000" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: volunteers referred to the clinical section of the Laboratory of Oral Medicine (National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland, USA) by private practitioners of medicine and dentistry.</P>
<P>Age: &lt; 36 years (5 in tetracycline group/8 in placebo group); &gt; 35 years (6 in tetracycline group/6 in placebo group)</P>
<P>Gender: 14 females/11 males (4 females/7 males in tetracycline group; 10 females/4 males in placebo group)</P>
<P>Inclusion criteria: willing to keep daily ulcer record charts and weekly appointments for 20 weeks; RAS for at least 1 year and not free of ulcers for longer than 2 weeks during the preceding 6 months</P>
<P>Exclusion criteria: presence of any other mucous membrane ulcerative disease or a skin disease possibly associated with oral lesions; finding of any physical or mental abnormality by the examining physician which would interfere with or be affected by the study procedures</P>
<P>Number randomised: 35</P>
<P>Number analysed: 25</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-13 10:52:26 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: tetracycline versus placebo</P>
<P> </P>
<P>Gr A (n = 11): tetracycline suspension 5 ml teaspoon containing 250 mg tetracycline held in the mouth for 2 minutes and then swallowed, 4 times per day at new ulcer outbreak, and continue for 20 doses (5 days). Also instructed not to take anything orally for 30 minutes following each treatment</P>
<P>Gr B (n = 14): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 13:37:30 +0000" MODIFIED_BY="[Empty name]">
<P>Ulcer duration, pain, number, size</P>
<P> </P>
<P>Duration of follow-up: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:55:06 +0100" MODIFIED_BY="[Empty name]">
<P>Selection of patients was not based on the severity of their disease</P>
<P>Patients were not divided according to the predominant type of ulceration - major or minor</P>
<P>Exclusion of participants with systemic disease not explicit</P>
<P>Reported at ulcer level</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:55:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamazaki-2006">
<CHAR_METHODS MODIFIED="2012-03-26 12:50:03 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Toyamama, Japan</P>
<P>Number of centres: 1 (please check as AMG put 2)</P>
<P>Funding: Science and Technology Agency of Japan</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-03 00:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: internet/newspaper adverts</P>
<P>Age: mean 42 years (range = 21 to 70)</P>
<P>Gender: 22 females/8 males</P>
<P>Inclusion criteria: minor RAS at least once per month</P>
<P>Exclusion criteria: allergy and/or autoimmunity</P>
<P>Number randomised: 33</P>
<P>Number analysed: 30</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:55:20 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: perilla cooking oil versus soybean cooking oil</P>
<P>Gr A (n = 17): perilla oil as only cooking oil</P>
<P>Gr B (n = 16): soybean oil as only cooking oil</P>
<P>Recruited participants were asked to maintain their body weight and physical activity levels</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 13:07:28 +0100" MODIFIED_BY="[Empty name]">
<P>Prevalence of minor RAS, resolution, fatty acid/dietary analysis, adverse effects</P>
<P> </P>
<P>Duration of follow-up: 8 months treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:55:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if ulcer or patient level data</P>
<P>Summary data for prevalence of aphthae not available, presented as figures only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:55:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolseth-2005">
<CHAR_METHODS MODIFIED="2012-03-26 13:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Oslo, Norway</P>
<P>Number of centres: 1</P>
<P>Funding: supported by Paramedical A/S Denmark</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-26 13:26:34 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: national newspaper and patient register of Faculty of Dentistry, University of Oslo, Norway</P>
<P>Age: mean 42 years (range = 16 to 75)</P>
<P>Gender: 32 females/20 males</P>
<P>Inclusion criteria: minor RAS based on disease history and clinical inspection during a 60-day introduction period (at least 1 attack during this period)</P>
<P>Exclusion criteria: no severe physical or psychological illness, or oral disease apart from RAS; patients who had taken LongoVital or any other systemic medication for RAS in the preceding 3 months</P>
<P>Number randomised: 60</P>
<P>Number analysed: 52</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:55:44 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: LongoVital (vitamin/herbal supplement) versus LongoVital (herbal component alone) versus placebo</P>
<P>Gr A (n = 20): LongoVital (vitamin/herbal supplement) - 3 tablets each morning</P>
<P>Gr B (n = 20): LongoVital (herbal component alone) - 3 tablets each morning</P>
<P>Gr C (n = 20): placebo - 3 tablets each morning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-10 12:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer-free days, new ulcers, immunological parameters, patient's preference</P>
<P> </P>
<P>Duration of follow-up: 8 months (4 months treatment, 4 months follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 15:55:33 +0100" MODIFIED_BY="[Empty name]">
<P>Summary data reported as medians with 95% CI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:56:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koray-2009">
<CHAR_METHODS MODIFIED="2012-03-13 14:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>Location of trial: Turkey</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 14:38:09 +0000" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: not stated</P>
<P>Age: mean 42.6 years</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: not stated</P>
<P>Exclusion criteria: presence of any significant local or systemic disease</P>
<P>Number randomised: 31</P>
<P>Number analysed: 31</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:56:03 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: beta-glucan versus placebo</P>
<P>Gr A (n = 21): 10 mg 1.3 to 1.6 beta-glucan twice per day for 20 days</P>
<P>Gr B (n = 10): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-10 12:21:03 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer severe score (USS compound scale of number, duration, ulcer-free days, site and pain); lymphocyte proliferation</P>
<P> </P>
<P>Duration of follow-up: 20 days treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:43 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-13 10:52:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lalla-2012">
<CHAR_METHODS MODIFIED="2012-07-04 14:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Connecticut, USA</P>
<P>Number of centres: 1</P>
<P>Funding: The Patrick and Catherine Weldon Donaghue Medical Research Foundation, NIH General Clinical Research Center and NIH career development grant</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: sample size of at least 50 participants per group (after accounting for drop-outs) needed to detect at least 65% probability that those receiving multivitamin intervention had a better outcome to those receiving placebo; power = 0.80 at 5% significance level</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-13 10:52:46 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: from general population of Hartford County, Connecticut, via flyers, emails to health center community and advertisements in local newspapers</P>
<P>Age: range = 18 to 72</P>
<P>Gender: 104 females/56 males</P>
<P>Inclusion criteria: validated history of at least three episodes of idiopathic minor RAS within the previous twelve months</P>
<P>Exclusion criteria: smoking, pregnancy, regular use of vitamin supplements or any over the counter or prescription agents for RAS, and a diagnosis of a systemic condition that can cause oral ulceration</P>
<P>Number randomised: 160</P>
<P>Number analysed: 160 (analysis on intention-to-treat basis despite 25 drop-outs in Gr A and 21 in Gr B)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:56:15 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: multivitamin versus placebo (lactose powder)</P>
<P>Gr A (n = 83): generic multivitamin supplement containing the US reference daily intake of essential vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, D, E</P>
<P>Gr B (n = 77): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-13 10:52:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: number and duration of RAS episodes during the 1-year study period</P>
<P>Secondary: mouth pain and normalcy of diet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-02 16:10:22 +0100" MODIFIED_BY="[Empty name]">
<P>Compliance an issue</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:56:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2004">
<CHAR_METHODS MODIFIED="2012-03-26 16:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Beijing, China</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-09 12:19:32 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients attending the China-Japan Friendship Hospital between January 2002 and September 2002</P>
<P>Age: range = 14 to 65 (no mean or SD reported)</P>
<P>Gender: 39 females/21 males</P>
<P>Inclusion criteria: patients diagnosed with RAS</P>
<P>Exclusion criteria: severe RAS; Behçet's disease; anaemia; peptic ulcer; acute infective disease; autoimmune disease; taken analgesics within 24 hours; taken antibiotics within 1 month; taken steroids or immunosuppressants within 3 months</P>
<P>Number randomised: 60</P>
<P>Number analysed: 60</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:56:33 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: rofecoxib versus tinidazole (control)</P>
<P>Gr A (n = 30): oral rofecoxib for 4 days - 50 mg on first day and 25 to 50 mg per day on the following days</P>
<P>Gr B (n = 30): oral tinidazole 1 g per day for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-10 15:56:35 +0100" MODIFIED_BY="[Empty name]">
<P>Total effective rate; pain intensity (VAS); ulcer size (diameter); diet scores</P>
<P>Duration of follow-up: 4 days treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-13 10:53:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyer-1977">
<CHAR_METHODS MODIFIED="2012-03-27 11:49:38 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Deurne, Belgium</P>
<P>Number of centres: 1</P>
<P>Funding: Janssen Pharmaceutica supplied the samples</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-04 11:41:03 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: not clearly stated</P>
<P>Age: median 41 years; range = 14 to 68</P>
<P>Gender: 87 male/37 female</P>
<P>Inclusion criteria:Had suffered RAS for years, at least one episode per month</P>
<P>Exclusion criteria: not discussed</P>
<P>Number randomised: 124</P>
<P>Number analysed: 124</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-13 10:53:18 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 75): 50 mg levamisole</P>
<P>Gr B (n = 49): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-08-10 15:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Number of RAS episodes per month; duration of episodes; number of lesions per episode; pain; changes in diameter of lesions</P>
<P> </P>
<P>Duration of follow-up: end of each month, complete study 4 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:32 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion of participants with systemic disease not explicit</P>
<P>Cumulative data rather than month/month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 15:59:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1978">
<CHAR_METHODS MODIFIED="2012-03-27 12:04:32 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Pennsylvania, USA</P>
<P>Number of centres: 1</P>
<P>Funding: grants from Janssen Pharmaceutical Company and National Institutes of Health, National Research Service Award</P>
<P>Trial ID: 1 T32 DE07036</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-27 12:12:11 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: Department of Oral Medicine, University of Pennsylvania, Philadelphia, USA</P>
<P>Age: mean 38.7 years</P>
<P>Gender: 15 females/5 males </P>
<P>Inclusion criteria: severe RAS defined as minimum of 12 episodes per year; previous visual confirmation of oral lesions; no self-referrals; older than 18 years of age</P>
<P>Exclusion criteria: evidence of concomitant disease or any condition which may be contributory to the ulcers</P>
<P>Number randomised: 32</P>
<P>Number analysed: 20</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 15:59:50 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 10): levamisole 150 mg for 11 days followed by 11 day period of no drug intake. This 2-week schedule was continued for duration of treatment (with reduction of dosage as required)</P>
<P>Gr B (n = 10): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-27 12:30:19 +0100" MODIFIED_BY="[Empty name]">
<P>Mean number of ulcers; duration</P>
<P> </P>
<P>Duration of follow-up: minimum 9 week treatment (unclear)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:25 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:00:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mousavi-2009">
<CHAR_METHODS MODIFIED="2012-03-27 12:33:44 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Tehran, Iran</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-09 12:19:37 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients referred to the Oral Medicine Clinic of Tehran University, Iran, from March 2002 to March 2004</P>
<P>Age: not stated</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: 18 to 65 years old; presented with 1 to 5 aphthous ulcers of less than 24-hours duration; more than 5 episodes in the preceding year; ulcers diameter was not greater than 6 mm; not suffering from acute or chronic diseases of the oral mucosa</P>
<P>Exclusion criteria: concurrent clinical conditions; ulcers as a manifestation of a systemic disease process such as ulcerative colitis, Crohn's disease, Behçet's disease, or serious anaemia; history of alcohol or drug abuse; taking any narcotic analgesics; history of systemic immunosuppressive therapy</P>
<P>Number randomised: 100</P>
<P>Number analysed: 100</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:00:24 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: homeopathic medicine (individually tailored for each patient) versus placebo (identical sucrose globules)</P>
<P>Gr A (n = 50): single dose of homeopathic medicine in 6C dilution, in liquid form, diluted in 100 ml of water. The same dose was repeated after 12 hours</P>
<P>Gr B (n = 50): single placebo globule diluted in 100 ml of water and repeated after 12 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-27 16:58:48 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer size (clinical measurement); pain (VAS) - both measures converted to an efficacy index (EI) calculated as a percentage of the baseline value and evaluated<BR/>on a 4-rank scale:</P>
<OL>
<LI>Healed: EI = 100%</LI>
<LI>Marked improvement: 70 to 99%</LI>
<LI>Moderate improvement: 30 to 69%</LI>
<LI>No improvement: &lt; 30%</LI>
</OL>
<P> Duration of follow-up: intervention on day 1 with follow-up on days 4 and 6</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 16:00:28 +0100" MODIFIED_BY="[Empty name]">
<P>Individually tailored homeopathic treatments</P>
<P>Summary data for pain score and ulcer size presented as figure only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:01:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Olson-1978">
<CHAR_METHODS MODIFIED="2012-03-27 13:05:37 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: San Francisco, USA</P>
<P>Number of centres: 1</P>
<P>Funding: Janssen R &amp; D Inc supplied levamisole</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-27 13:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients referred to the Oral Medicine Clinic, University of California, San Francisco, USA</P>
<P>Age: not stated</P>
<P>Gender: 27 females/21 males</P>
<P>Inclusion criteria: RAS attacks at least every other month</P>
<P>Exclusion criteria: not stated</P>
<P>Number randomised: 48</P>
<P>Number analysed: 48</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 23): single dose of 1 tablet (50 mg per tablet) repeated 3 times per day for 3 days. Dosage was not repeated more often than weekly. New lesion had to be present to re institute therapy. Each patient repeated schedule for the course of 6 episodes of aphthae. Patients took no concurrent medication for their condition</P>
<P>Gr B (n = 25): identical placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-27 16:59:04 +0100" MODIFIED_BY="[Empty name]">
<P>Days between attacks (frequency); duration; pain (self-assessed); investigator's clinical evaluation of patient's subjective treatment response</P>
<P> </P>
<P>Duration of follow-up: variable</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:01:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pakfetrat-2010">
<CHAR_METHODS MODIFIED="2012-03-27 14:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Tehran and Mashhad, Iran</P>
<P>Number of centres: 2</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: sample size of 17 patients in each group, power = 0.80</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-27 15:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: oral medicine clinics of 2 universities including Tehran and Mashhad dental schools</P>
<P>Age: mean 31 years</P>
<P>Gender: 22 females/12 males</P>
<P>Inclusion criteria: history of RAS (at least 3 episodes per month); unresponsive to conventional topical treatments; no medication taken to treat RAS in 2 weeks prior to beginning of the study; 18 years or over; normal biochemical screening</P>
<P>Exclusion criteria: previous medical history of systemic disease; taken medication which may affect the immune system; involvement of other mucous membranes</P>
<P>Number randomised: 34</P>
<P>Number analysed: 34</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:01:13 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: colchicine versus prednisolone</P>
<P>Gr A (n = 17): 0.5 mg colchicine per day for 3 months</P>
<P>Gr B (n = 17): 5 mg prednisolone per day for 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-27 15:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>Size; number of lesions; recurrence; intensity of pain; burning sensation; side effects</P>
<P> </P>
<P>Duration of follow-up: 12 weeks treatment, assessed at 2-week intervals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:53:04 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:01:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pourahmad-2010">
<CHAR_METHODS MODIFIED="2012-03-27 15:45:42 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Jahrom, Iran</P>
<P>Number of centres: 1</P>
<P>Funding: Shifoo Company produced camel thorn distillate (intervention); financial support from Jahrom University of Medical Sciences</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-09 12:19:42 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients presenting to the Internal Medicine Clinic at Jahrom University of Medical Sciences for evaluation and treatment of RAS</P>
<P>Age: mean 27.4 years in camel thorn group; mean 31.8 years in placebo group</P>
<P>Gender: 44 females/49 males (22 females/27 males in camel thorn group; 22 females/22 males in placebo group)</P>
<P>Inclusion criteria: an aphthous lesion on oral mucosa and history of recurrent similar lesions</P>
<P>Exclusion criteria: presence of the lesion for more than 3 days prior to presentation; use of medication prior to presentation; Behçet's disease or other autoimmune disorder (or history of); lack of compliance with/discontinuation of study drug; long distance between the patient's home and clinic (which may affect ability to return for follow-up visits); children or very elderly (unlikely to be able reliably report severity of pain); if lesions were suspected to be herpes simplex ulcers</P>
<P>Number randomised: 93</P>
<P>Number analysed: 93</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:01:41 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: camel thorn distillate versus placebo (distilled water)</P>
<P>Gr A (n = 49): 40 ml solution 4 times per day until complete resolution of symptoms (drug held in the mouth for 1 minute and then swallowed)</P>
<P>Gr B (n = 44): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-27 16:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Size of lesions (diameter); pain intensity (0 to 10 numerical rating scale); time to complete resolution of symptoms (when lesion diameter and pain = 0); side effects</P>
<P> </P>
<P>Duration of follow-up: up to 14 days (or complete resolution if sooner)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:52:59 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:02:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Preshaw-2007">
<CHAR_METHODS MODIFIED="2012-03-27 16:37:17 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Newcastle, UK</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: power = 0.85 for 20 participants in each group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-27 16:51:42 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients presenting with long-term history of RAS at the Oral Medicine Clinic at Newcastle Dental Hospital</P>
<P>Age: mean 40 years (range = 18 to 64)</P>
<P>Gender: 32 females/18 males</P>
<P>Inclusion criteria: history of RAS necessitating appointments on oral medicine clinic more than 2 times per year</P>
<P>Exclusion criteria: deficiencies in serum ferritin, vitamin B12 and/or folate; pregnant or nursing (lactating) women; known hypersensitivity to tetracyclines; women of child-bearing potential not taking adequate contraceptive precautions; taking clinically significant concomitant drugs; patients with diabetes mellitus, systemic infection, kidney or liver disease; patients requiring prophylactic antibiotic coverage for routine dental therapy</P>
<P>Number randomised: 50</P>
<P>Number analysed: 50</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:01:54 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: subantimicrobial dose doxycycline versus placebo (identical in appearance)</P>
<P>Gr A (n = 25): subantimicrobial dose doxycycline 20 mg twice daily for 90 days</P>
<P>Gr B (n = 25): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-27 16:55:25 +0100" MODIFIED_BY="[Empty name]">
<P>Number of new ulcers; pain (VAS); additional ulcer treatment</P>
<P> </P>
<P>Duration of follow-up: 90 days treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 16:02:06 +0100" MODIFIED_BY="[Empty name]">
<P>Data presented at 90-day end of treatment and over treatment period</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:02:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samet-2007">
<CHAR_METHODS MODIFIED="2012-03-27 17:06:42 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Boston, USA</P>
<P>Number of centres: 1</P>
<P>Funding: not stated</P>
<P>Trial ID: IRB #M10778-101</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated (pilot study)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-09 12:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients presenting for treatment at Harvard School of Dental Medicine clinics, members of the local community, and word-of-mouth referrals, recruited over a 10-month period</P>
<P>Age: not stated (at least 18 years old at the time of enrolment)</P>
<P>Gender: not stated</P>
<P>Inclusion criteria: at least 18 years old at the time of enrolment; RAS not associated with other conditions (e.g. anaemia, vitamin deficiencies, inflammatory bowel disease, celiac disease, Behçet's disease, Reiter's disease, or HIV-associated immunosuppression)</P>
<P>Exclusion criteria: history of allergy to propolis, bee products, or bee sting</P>
<P>Number randomised: 19</P>
<P>Number analysed: 19</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: bee propolis versus placebo (calcium-based food supplement)</P>
<P>Gr A (n = 10): bee propolis 1 capsule (500 mg) per day</P>
<P>Gr B (n = 9): placebo as for Gr A</P>
<P>Patients asked not to use any other product for the prevention or treatment of aphthous ulcers while participating in this study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-27 16:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>Frequency of RAS outbreaks (self-reported); number of new ulcers; duration; subjective severity (1 to 10 scale); patient-reported improvement in quality of life</P>
<P> </P>
<P>Duration of follow-up: 6 months treatment (minimum i.e. some were longer)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:52:38 +0100" MODIFIED_BY="[Empty name]">
<P>Pilot study</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:02:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thornhill-2007">
<CHAR_METHODS MODIFIED="2012-03-28 14:55:22 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Manchester, UK</P>
<P>Number of centres: 1</P>
<P>Funding: Hoechst Marion Roussel provided pentoxifylline and matching placebo tablets</P>
<P>Trial ID: NCT00315679</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 15:43:38 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: posters in offices or surgical areas of general medical and general dental practitioners in the Greater Manchester area, then screened for suitability using standardised telephone questionnaire</P>
<P>Age: overall range = 18 to 55 years; overall mean 33 years (SD 10.2); mean 34 years (SD 8.1) in pentoxifylline group (range = 21 to 55); mean 33 years (SD 12.6) in placebo group (range 18 to 53)</P>
<P>Gender: 17 females/9 males (9 females/5 males in pentoxifylline group; 8 females/4 males in placebo group)</P>
<P>Inclusion criteria: more than 2 ulcers per month for more than 6 months; no current treatment for ulceration or a willingness to stop the current treatment; aged 16 to 65 years; not taking ketorolac, theophylline or antihypertensive medications except diuretics (contraindicated in patients taking pentoxifylline); no underlying systemic conditions which would contraindicate taking pentoxifylline (e.g. pregnancy, hypotension, ischaemic heart disease, allergy to pentoxifylline, etc)</P>
<P>Exclusion criteria: see inclusion criteria</P>
<P>Number randomised: 26</P>
<P>Number analysed: 26 (intention-to-treat analysis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:02:37 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: pentoxifylline versus placebo (identical)</P>
<P>Gr A (n = 14): 400 mg tablet of pentoxifylline 3 times per day with food for 60 days</P>
<P>Gr B (n = 12): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 15:31:55 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer number; size; number of episodes; pain (10-point scale)</P>
<P> </P>
<P>Duration of follow-up: 180 days (60 days treatment and 60 days follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:52:33 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:02:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-de-Heyning-1978">
<CHAR_METHODS MODIFIED="2012-06-08 14:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Turnhout, Belgium</P>
<P>Number of centres: not stated/unclear</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-08 16:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: not stated</P>
<P>Age: mean 33.6 years in levamisole group (range = 20 to 53); mean 32.8 years in placebo group (range = 18 to 45)</P>
<P>Gender: 9 females/4 males (5 females/2 males in levamisole group; 4 females/2 males in placebo group)</P>
<P>Inclusion criteria: at least 1 aphthous lesion per month in the preceding year</P>
<P>Exclusion criteria: not stated</P>
<P>Number randomised: 13</P>
<P>Number analysed: 13</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:02:57 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo (identical)</P>
<P>Gr A (n = 7): levamisole 50 mg 3 times per day for 3 consecutive days, repeated every other week for 2 months (36 tablets given to each participant)</P>
<P>Gr B (n = 6): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-08 16:43:26 +0100" MODIFIED_BY="[Empty name]">
<P>Ulcer frequency; duration; number; pain (all recorded by patient on a diary card)</P>
<P> </P>
<P>Duration of follow-up: 2 months treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 16:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>Exclusion of participants with systemic disease not explicit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-13 10:53:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volkov-2009">
<CHAR_METHODS MODIFIED="2012-03-28 15:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: the Negev, Israel</P>
<P>Number of centres: not stated/unclear</P>
<P>Funding: Solgar (pharmaceutical company) provided "partial funding"</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: power = 0.80 for 24 participants in each group (given the assumption of a 'no aphthous ulcers status' of 73% among patients in the intervention group and 30% of those in control group)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-08-13 10:53:32 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: personal letters sent by email from 20 family physicians</P>
<P>Age: mean 33.1 years (SD 9.57) in vitamin B12 group (range = 21 to 62); mean 29.15 years (SD 6.61) in placebo group (range = 18 to 47)</P>
<P>Gender: 29 females/29 males (15 females/16 males in vitamin B12 group; 14 females/13 males in placebo group)</P>
<P>Inclusion criteria: older than 18 years; suffering from RAS for at least 1 year (at least 1 outbreak every 2 months)</P>
<P>Exclusion criteria: known systemic diseases concurrent with lesions in the mouth (Behçet's disease, rheumatoid arthritis, lupus, AIDS); received treatment with vitamin B12 in any form for the last year; received other concurrent treatment for aphthous ulcers; were pregnant or nursing; had Leber's optic atrophy; suffered from psychosis; or had a known vitamin B12 deficiency</P>
<P>Number randomised: 58</P>
<P>Number analysed: 52</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: sublingual vitamin B12 versus placebo (same ingredients except for the vitamin B12)</P>
<P>Gr A (n = 27): vitamin B12 1000 mcg in a 100 mg tablet once daily before going to sleep for 6 months</P>
<P>Gr B (n = 25): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 16:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>Average duration (days) of an aphthous stomatitis episode; monthly number of aphthous ulcers; severity of pain (patient assessed) according to the Numerous Rating Scale (NRS); side effects</P>
<P> </P>
<P>Duration of follow-up: 6 months treatment (with monthly follow-up)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 16:03:20 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if mean or median data presented. No variance presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:03:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weckx-2009">
<CHAR_METHODS MODIFIED="2012-03-28 16:31:21 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: São Paulo, Brazil</P>
<P>Number of centres: 1</P>
<P>Funding: unknown (translated)</P>
<P>Trial ID: unknown (translated)</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-28 16:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: patients presenting with recurrent aphthae at the Stomatology Outpatient Sector of the Federal University of São Paulo/Paulista School of Medicine</P>
<P>Age: mean 39.1 years in levamisole group (range = 17 to 83); mean 25.9 years in placebo group (range = 12 to 46)</P>
<P>Gender: 17 females/7 males (9 females/5 males in levamisole group; 8 females/2 males in placebo group)</P>
<P>Inclusion criteria: RAS (minor form) at least episode per month for the past 12 months</P>
<P>Exclusion criteria: contraindications to the use of levamisole; pregnant women</P>
<P>Number randomised: 28</P>
<P>Number analysed: 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:03:35 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus placebo</P>
<P>Gr A (n = 14): levamisole 150 mg on Mondays, Wednesdays and Fridays in the first 4 weeks, then on alternate weeks from the 5th to 12th week, then every 3 weeks from the 13th to 24th week</P>
<P>Gr B (n = 10): placebo as for Gr A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-27 17:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>Frequency of episodes per month; number of lesions per episode; duration in days of each episode; pain; adverse effects; medical evaluation</P>
<P> </P>
<P>Duration of follow-up: 25 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-08-10 16:03:53 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if mean or median vales presented</P>
<P>Exclusion of participants with systemic disease not explicit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-08-10 16:05:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zissis-1983">
<CHAR_METHODS MODIFIED="2012-03-28 17:01:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location of trial: Thessaloniki, Greece</P>
<P>Number of centres: not stated</P>
<P>Funding: not stated</P>
<P>Trial ID: not stated</P>
<P>Type of RCT: parallel</P>
<P>Power calculation: not stated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-27 17:00:34 +0100" MODIFIED_BY="[Empty name]">
<P>Source of recruitment: not stated (recruited over 6-month period)</P>
<P>Age: median 32 years in Gr A; median 25 years in Gr B; median 31 years in Gr C</P>
<P>Gender: 20 females/13 males (10 females/3 males in Gr A; 4 females/7 males in Gr B; 6 females/3 males in Gr C)</P>
<P>Inclusion criteria: at least 1 episode monthly during past 6 months</P>
<P>Exclusion criteria: history of agranulocytosis due to drug intake; pregnant women</P>
<P>Number randomised: 33</P>
<P>Number analysed: unclear ("Two patients in group A and two patients in group B interrupted their treatment early because of unwanted effects but they were followed-up for the whole 16 week observation period and they were evaluated separately. After stopping their treatment, side effects subsided and from the point of view of disease severity, they returned to their pre-trial condition")</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-08-10 16:05:05 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison: levamisole versus levamisole plus placebo versus placebo</P>
<P>All groups took medication (all identical) for 2 consecutive days per week (given 2 vials numbered 1 and 2 - first day medication taken from vial 1 and the next day from vial 2)</P>
<P>Gr A (n = 13): levamisole 50 mg 3 times per day for days 1 and 2</P>
<P>Gr B (n = 11): levamisole 50 mg 3 times per day for day 1 and placebo tablet 3 times per day for day 2</P>
<P>Gr C (n = 9): placebo tablet 3 times per day for days 1 and 2</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 17:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of ulcers (days); frequency of episodes per month; number of ulcers in each episode; ulcer size; pain (0 to 4 scale); adverse effects</P>
<P> </P>
<P>Duration of follow-up: 16 weeks treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-27 17:00:57 +0100" MODIFIED_BY="[Empty name]">
<P>Inconsistencies if data presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AIDS = acquired immune deficiency syndrome<BR/>CI = confidence interval<BR/>HIV = human immunodeficiency virus<BR/>NSAIDs = nonsteroidal anti-inflammatory drugs<BR/>RAS = recurrent aphthous stomatitis<BR/>RCT = randomised controlled trial<BR/>SD = standard deviation<BR/>VAS = visual analogue scale<BR/>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-08-09 14:22:15 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-08-09 10:09:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolby-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 10:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>Following discussion the mode of action was considered to be primarily topical (tablets of cromoglycic acid allowed to dissolve slowly in the mouth)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 14:22:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kowolik-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 14:22:00 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with no washout period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 14:22:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lehner-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 14:22:03 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with no washout period</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-04 15:07:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nolan-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-04 15:07:57 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 14:22:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedersen-1990a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 14:22:13 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with no washout period and potential for confounding with multivitamins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 14:22:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pedersen-1990b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 14:22:15 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study with no washout period and potential for confounding with multivitamins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-04 15:08:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raeste-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-04 15:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-08 14:01:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sharquie-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-08 14:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>No mention of the word 'random'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-09 10:10:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-09 10:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>Following discussion the mode of action was considered to be primarily topical (local botulinum toxin A injection)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-08-13 10:52:22 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-27 17:59:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 09:56:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Quote: "...stratified according to the minimization method..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:34:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 11:48:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:00:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:46:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Quote: "...random number generator program on a computer..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:05:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>Quote: "A pharmacist dispensed the medication according to a series of random numbers prepared by the statistician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:52:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:57:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:04:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 17:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>Quote: "computer-based pseudorandom number generator"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:10:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:30:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:19:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:25:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Quote: "...computer generated random list..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:29:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:38:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>Quote: "To guarantee blinding a random number was generated for each participant using SPSS software"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:44:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:51:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>Quote: "A predetermined computer generated randomisation schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:06:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:56:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Quote: "computer generated random number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-08 16:44:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:57:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>Quote: "...batch numbers generated by a computer program"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:18:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>Quote: "randomly by drawing lots"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:01:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:26:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-27 18:01:47 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 09:58:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:34:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 11:49:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:00:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:47:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Quote: "...different operator...allocated patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:07:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>Quote: "A pharmacist dispensed the medication according to a series of random numbers prepared by the statistician. Numbers were assigned consecutively to the patients at the beginning of the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:52:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:57:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:04:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 18:01:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>Quote: "research pharmacist assigned participants..." and "kept confidential records of study drug assignment..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:10:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:31:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:19:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:24:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:30:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:39:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>Quote: "Patients were referred to the pharmacist to pick up their assigned medication according to their number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:46:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>Quote: "...patient was sent to pharmacy to obtain their study drug"</P>
<P>Comment: unclear if allocation was concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:51:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:06:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:57:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Third party allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-08 16:44:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:57:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:18:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:01:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:27:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-08-13 10:52:19 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 10:04:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 10:35:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>Quote: "...all tablets were identical in appearance..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 11:51:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>Quote: "The code for identifying active and placebo tablets, which looked identical, were kept in individually marked containers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-27 11:02:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: treatment B differs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-08-13 10:52:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Quote: "...an identical white container..."</P>
<P>However, the trial arms used different drug regimen so incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 12:07:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>Placebo suspension</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 14:53:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 14:58:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>Quote: "The tablets were coated to make them indistinguishable from each other"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:06:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-27 18:09:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>Identical placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:11:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>Quote: "...single-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 12:31:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>Quote: "Tablets looked identical and were supplied in identical coded bottles"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:21:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Quote: "...neither of the investigators directly involved in patient management had access to the code book..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:28:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Patients-only blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:34:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>Quote: "...active and placebo tablets were obviously identical except for the presence or absence of levamisole"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:40:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>Quote: "All tablets were enclosed in identical sealed dark boxes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:46:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>Quote: "...solutions were placed in identical containers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:52:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>Quote: "Placebo and SDD tablets were identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-27 11:08:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>Quote: "neither the participants nor the investigators knew the identity of the product distributed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 15:58:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Quote: "drug and placebo control...identical oblong pink tablets"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-08 16:52:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: insufficient description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 13:00:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>Quote: "The physicians and the participants were blinded to the group assignment until the study ended", "...types of tablets were the same in shape, size, color, and flavor"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 14:19:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 16:02:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: insufficient description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-01-26 10:27:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>Quote: "...partially blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-08-13 10:52:22 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 10:04:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 10:36:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 11:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-27 11:02:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: treatment B differs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-13 10:52:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Quote: "All patients and all subsequent investigators...did not know the therapy used for each group"</P>
<P>However, the trial arms used different drug regimen so incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 12:08:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 14:55:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:01:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:06:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-27 18:07:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>"research pharmacist assigned participants..." and "kept confidential records of study drug assignment...", "not accessible to study investigators during the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:12:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>Quote: "...single-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 12:32:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:20:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Code not known by outcomes assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:26:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Outcomes assessment carried out by investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:34:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>Quote: "...codes broken when the patient completed the sixth episode of double-blind medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:41:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:47:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:53:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>Patient reported outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-27 11:09:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>Quote: "neither the participants nor the investigators knew the identity of the product distributed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 15:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Quote: "trial number not released by pharmacy until after the study had been completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-08 16:52:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: insufficient description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 13:10:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>Quote: "The physicians and the participants were blinded to the group assignment until the study ended"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 14:19:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-01-26 16:01:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>Quote: "...double-blind..."</P>
<P>Comment: no description in text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-08-13 10:51:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>Quote: "A physician who was not aware of the drug regimen of the patients also rated their improvement..."</P>
<P>However, the trial arms used different drug regimen so incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-08-02 22:03:33 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-08-02 22:03:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 10:08:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Minimal drop-out. Unlikely to alter estimate of effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 10:51:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>Unclear whether there were any drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 11:52:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>4/15 in active group and 2/15 in placebo group not evaluated </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-27 11:03:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>Quote: "no drop-outs"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 14:50:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>No patient drop-out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 12:15:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>10 out of 35 patients dropped out; unclear as to which group they were assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 14:55:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>3/30 patients not included in analysis but reasons given and unlikely to alter findings</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:02:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>2/20, 4/20 and 2/20 patients withdrew from group A, B and C respectively. 4 of the withdrawals in group A and B were due to indigestion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:06:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>All randomised participants included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-04 14:01:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>25/83 participants in the intervention group and 21/77 participants in the placebo group dropped-out. Reasons not stated but analysis carried out on intention-to-treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:12:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>All patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 12:41:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>9 drop-outs but no discrepancies between groups (levamisole: 4/32; placebo: 5/39); however, no pain data at month 4 for 7/39 in placebo group compared to 2/32 in the active group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:22:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Only subjects who participated for at least 9 weeks were included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:28:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:36:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>Quote: "...patients who had been on levamisole continued if they had experienced improvement and were dropped from the study if they had not"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:43:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>All patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:48:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>Insufficient information regarding patients analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 15:54:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>All patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-27 11:10:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>Uneven drop-outs; unclear if intention to treat analysis undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-29 15:43:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Intention-to-treat analysis undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-08 16:47:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>No drop-outs</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 13:06:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>27/31 in the intervention group and 25/27 in the placebo group completed the study, therefore no discrepancies in drop-out between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 14:22:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>4/28 drop-outs; group not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 16:03:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>All patients included in analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-26 10:32:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>No intention-to-treat. Imbalance in drop-outs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-08-02 22:03:33 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 16:57:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Insufficient information; some confusion regarding timing of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:50:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>Pain not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 11:53:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>Pain not reported. Standard deviations not reported. Duration of lesions not reported for all visits</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 17:48:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>Number of days to pain cessation measured using VAS but pain intensity not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:50:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Important outcomes reported but not for all time points</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:23:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>Adjusted means only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:55:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>Not all important outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:02:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>Pain not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:07:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>Compound score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 18:06:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>Important outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:14:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>Only reported on pain</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:43:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:22:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Pain not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:28:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:36:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:43:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:48:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:54:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-09 20:56:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>Duration and perceived severity of ulcers not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:00:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>Compound score</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-08 16:47:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 13:07:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>Main outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:31:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>Composite value for clinical improvement reported without any definition of composite value</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:06:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>Inconsistencies in presented data in the tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-04-12 14:49:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>No detail regarding lesion size, despite being listed as outcome assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-08-02 22:03:33 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 16:57:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bratel-2005">
<DESCRIPTION>
<P>Potential bias with regards to the use of co-interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:56:29 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Cree-1978">
<DESCRIPTION>
<P>No other apparent biases but poorly reported study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 11:58:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Drinnan-1978">
<DESCRIPTION>
<P>Some patients reported continuous ulcers so unable to assess ulcer-free time. The mean number of days between episodes was greater in the placebo group than in the active group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:05:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2003">
<DESCRIPTION>
<P>Potential imbalance with regard to gender</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:51:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Femiano-2010">
<DESCRIPTION>
<P>Imbalance in gender between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-02 16:05:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graykowski-1978">
<DESCRIPTION>
<P>Analysis at ulcer level with no accounting for cluster </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:55:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hamazaki-2006">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:03:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kolseth-2005">
<DESCRIPTION>
<P>Use of alleviating drugs, mainly corticosteroids and antiseptic mouthwash. Study was supported by Paramedical A/S, Denmark</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:07:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koray-2009">
<DESCRIPTION>
<P>Study reported as letter to editor; little information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-27 18:06:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lalla-2012">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:16:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2004">
<DESCRIPTION>
<P>Length of treatment time differs between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 12:44:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Meyer-1977">
<DESCRIPTION>
<P>Imbalance in gender and smoking habits between groups at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:23:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Miller-1978">
<DESCRIPTION>
<P>Difference in mean number of days in study. Gender imbalance at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:29:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mousavi-2009">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:37:09 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Olson-1978">
<DESCRIPTION>
<P>Confusion regarding dropping of patients, plus "most people assessed for 4 of 6 episodes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:43:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakfetrat-2010">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:49:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pourahmad-2010">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 15:55:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Preshaw-2007">
<DESCRIPTION>
<P>Quote: "All subjects were permitted to use any additional ulcer management therapies at any time during the study"</P>
<P>Pharma as co-author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-27 11:11:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Samet-2007">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:00:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thornhill-2007">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-08 16:49:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-de-Heyning-1978">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 13:12:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volkov-2009">
<DESCRIPTION>
<P>Quote: "Solgar pharmaceutical company provided partial funding for this study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 14:56:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Weckx-2009">
<DESCRIPTION>
<P>No other apparent biases but poorly reported study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 16:04:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zissis-1983">
<DESCRIPTION>
<P>No other apparent biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-26 10:26:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Abreu-2009">
<DESCRIPTION>
<P>No comparison at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-08-13 10:48:56 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-08-10 16:13:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-04-02 21:10:08 +0100" MODIFIED_BY="[Empty name]">Summary of results not suitable for meta-analysis</TITLE>
<TABLE COLS="4" ROWS="31">
<TR>
<TD>
<P>
<B>Study ID</B>
</P>
</TD>
<TD>
<P>
<B>Comparison</B>
</P>
</TD>
<TD>
<P>
<B>Summary of results</B>
</P>
</TD>
<TD>
<P>
<B>Harms</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Drinnan-1978" TYPE="STUDY">Drinnan 1978</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>Subjective results: 6/11 improved versus 5/13 improved</P>
</TD>
<TD>
<P>"eight subjects reported side effects (generally cacogeusia or nausea)" "no side effects warranted withdrawal"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-De-Cree-1978" TYPE="STUDY">De Cree 1978</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>"minor side effects included headache, nausea and a metallic taste, never necessitated the discontinuation of therapy"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Olson-1978" TYPE="STUDY">Olson 1978</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>No statistically significant difference between groups with regard to days between attacks, duration of lesions or patient's evaluation of pain. Investigators clinical evaluation of response to treatment was "significant with P &lt; 0.005"</P>
</TD>
<TD>
<P>"A total of 15 patients experienced some type of side effect during the double-blind study; 14 of these individuals were taking levamisole. None of the patients had side effects severe enough to warrant discontinuing the medication."</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weckx-2009" TYPE="STUDY">Weckx 2009</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>No statistically significant difference between groups with regard to number of episodes, number of lesions, duration of lesions or pain</P>
</TD>
<TD>
<P>"One patient heartburn/weakness, one patient diarrhoea in week 5"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zissis-1983" TYPE="STUDY">Zissis 1983</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus levamisole + placebo versus</P>
<P>placebo</P>
</TD>
<TD>
<P>Unclear due to inconsistency in the text. However, the authors report that "All parameters evaluated have been statistically improved in both levamisole groups"</P>
</TD>
<TD>
<P>"two patients in each group reported unwanted effects"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Meyer-1977" TYPE="STUDY">Meyer 1977</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>Statistically significant differences shown for number of episodes per month (P = 0.029), duration of episodes (P = 0.003), number of lesions/episodes (P &lt; 0.001), size of lesions (P &lt; 0.01) and degree of pain (P = 0.03) (Mann-Whitney U test)</P>
</TD>
<TD>
<P>"no one had to discontinue treatment because of side effects"</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Miller-1978" TYPE="STUDY">Miller 1978</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>"The t-tests comparing levamisole and placebo groups revealed no statistically significant difference (P &gt; 0.05) in mean number of ulcers, the mean number of ulcer days, the mean duration of ulcers, or the mean number of ulcers per day"</P>
</TD>
<TD>
<P>Adverse effects were experienced by seven of the levamisole subjects while none of the placebo group reported adverse effects. These effects included mild stomach upset or nausea, diarrhoea, sleeplessness and dysgeusia and/or dysosmia</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Van-de-Heyning-1978" TYPE="STUDY">Van de Heyning 1978</LINK>
</P>
</TD>
<TD>
<P>Levamisole versus placebo</P>
</TD>
<TD>
<P>See <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>
</P>
<P/>
<P>Decrease in frequency of attacks: RR 4.29 [95% CI 0.72 to 25.39; P = 0.11]</P>
<P/>
<P>Decrease in duration of attacks: RR 4.29 [95% CI 0.67 to 27.24; P = 0.12]</P>
<P/>
<P>Decrease in number of ulcers: RR 7.88 [95% CI 0.51 to 121.96; P = 0.14]</P>
<P/>
<P>Decrease in pain: RR 4.29 [95% CI 0.67 to 27.24; P = 0.12]</P>
</TD>
<TD>
<P>"No adverse effects were reported"</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Volkov-2009" TYPE="STUDY">Volkov 2009</LINK>
</P>
</TD>
<TD>
<P>Vitamin B12 versus placebo</P>
</TD>
<TD>
<P>"The duration of outbreaks, the number of ulcers, and the level of pain were reduced significantly (P &lt; 0.05) at 5 and 6 months."</P>
<P/>
</TD>
<TD>
<P>"no known significant toxic effects"</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thornhill-2007" TYPE="STUDY">Thornhill 2007</LINK>
</P>
</TD>
<TD>
<P>Pentoxifylline versus placebo</P>
</TD>
<TD>
<P>No statistically significant difference between groups for pain, number of ulcers, ulcer-free days and adverse effects. A statistically significant difference in ulcer size was seen, in favour of pentoxifylline</P>
</TD>
<TD>
<P>"69% reported adverse effects&#8230;. Dizziness, headaches, stomach upset, increased heart rate and nausea. However placebo patients reported similar complaints."</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Samet-2007" TYPE="STUDY">Samet 2007</LINK>
</P>
</TD>
<TD>
<P>Bee propolis versus placebo</P>
</TD>
<TD>
<P>"a statistically significant reduction of outbreaks in the propolis group (Fisher's exact test , one sided, P = 0.04). Patients in the propolis also self-reported a significant improvement in their quality of life (P = 0.03)"</P>
</TD>
<TD>
<P>"low rates of minimal side effects"</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pourahmad-2010" TYPE="STUDY">Pourahmad 2010</LINK>
</P>
</TD>
<TD>
<P>Camel thorn distillate versus placebo</P>
</TD>
<TD>
<P>Mean time to complete resolution was 4.02 (range 3 to 7 days) for camel thorn compared to 8.9 (7 to 14 days), P &lt; 0.001 (independent t-test).</P>
<P>A statistically significant difference in pain intensity also reported</P>
</TD>
<TD>
<P>"No evidence of drug side effects was observed"</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mousavi-2009" TYPE="STUDY">Mousavi 2009</LINK>
</P>
</TD>
<TD>
<P>Homeopathic medicine versus placebo</P>
</TD>
<TD>
<P>Statisitically significant (P &lt; 0.05) reduction in ulcer size and pain was reported for the homeopathic group</P>
</TD>
<TD>
<P>"No adverse drug reaction to a treatment solution was reported as a reason for leaving the study"</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Graykowski-1978" TYPE="STUDY">Graykowski 1978</LINK>
</P>
</TD>
<TD>
<P>Tetracycline versus placebo</P>
</TD>
<TD>
<P>"Both the placebo and tetracycline groups experienced reductions in ulcer incidence during the treatment period, whereas only the tetracycline group showed significant reductions in ulcer duration, size, and pain"</P>
</TD>
<TD>
<P>"side effects recorded in patients taking tetracycline were comparable to those in patients on placebo."<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lu-2004" TYPE="STUDY">Lu 2004</LINK>
</P>
</TD>
<TD>
<P>Rofecoxib versus tinidazole</P>
</TD>
<TD>
<P>"The healing rate of the treatment group after 2 days was significantly higher than that of the control group (P &lt; 0.05)....There was no significant differences of total effective rate after 4 days..." Means only presented for pain, size of ulcer at end of treatment but no standard deviations given. Results for these not given in translation</P>
</TD>
<TD>
<P>No adverse effects reported in translation</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kolseth-2005" TYPE="STUDY">Kolseth 2005</LINK>
</P>
</TD>
<TD>
<P>LongoVital (vitamin/herbal supplement) versus LongoVital (herbal component alone) versus placebo</P>
</TD>
<TD>
<P>"None of the treatment - response parameters showed any statistically significant differences between any of the groups at any of the test periods"</P>
</TD>
<TD>
<P>"Nine of the 52 patients in the study reported mild<BR/>indigestion problems at the very beginning of the tablet period and they were evenly distributed among the three groups."</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hamazaki-2006" TYPE="STUDY">Hamazaki 2006</LINK>
</P>
</TD>
<TD>
<P>Perilla cooking oil versus soybean cooking oil</P>
</TD>
<TD>
<P>No intergroup differences</P>
</TD>
<TD>
<P>No adverse events</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-de-Abreu-2009" TYPE="STUDY">de Abreu 2009</LINK>
</P>
</TD>
<TD>
<P>Clofazimine versus colchicine versus placebo</P>
</TD>
<TD>
<P>"A greater percentage of individuals in the clofazimine group had no further aphthous episodes (17% to 44% compared with &lt; = 6% in other groups)</P>
</TD>
<TD>
<P>"The clofazimine group showed greater percentage of cutaneous adverse effects (skin pigmentation and drying)&#8230;." "skin bronzing did not deter patients&#8230;. Dryness was easily controlled" "complaints of dryness"</P>
<P>"A significantly greater percentage of treatment interruption occurred in the colchicine group because of gastrointestinal effects."</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Femiano-2003" TYPE="STUDY">Femiano 2003</LINK>
</P>
</TD>
<TD>
<P>Sulodexide versus prednisone versus placebo</P>
</TD>
<TD>
<P>"The effectiveness of systemic sulodexide was almost comparable with that of systemic prednisone in patients with frequent RAS, without significant side effects"</P>
</TD>
<TD>
<P>No serious adverse events (one significant adverse event (gastritis) was reported for the group receiving prednisone compared to no significant adverse events for the placebo group)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI = confidence interval<BR/>RAS = recurrent aphthous stomatitis<BR/>RR = risk ratio<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-08-13 10:48:56 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-07-04 11:45:50 +0100" MODIFIED_BY="[Empty name]">Systemic agents used in the management of aphthous stomatitis</TITLE>
<TABLE COLS="3" ROWS="32">
<TR>
<TD VALIGN="TOP">
<P>
<B>Drug class/group</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Mode of action </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Notes</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Corticosteroids</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Prednisolone</P>
</TD>
<TD VALIGN="TOP">
<P>Anti-inflammatory</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Betamethasone</P>
</TD>
<TD VALIGN="TOP">
<P>Anti-inflammatory</P>
</TD>
<TD ROWSPAN="3" VALIGN="TOP">
<P>Studies of these corticosteroids were not found or included in the review but are included here for completeness. They are not given orally for this indication but some systemic absorption may occur</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Beclometasone diproprionate</P>
</TD>
<TD VALIGN="TOP">
<P>Anti-inflammatory</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Hydrocortisone</P>
</TD>
<TD VALIGN="TOP">
<P>Anti-inflammatory</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>NSAID</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rofecoxib</P>
</TD>
<TD VALIGN="TOP">
<P>Cox-2 inhibitor</P>
</TD>
<TD VALIGN="TOP">
<P>Withdrawn worldwide after reports of cardiovascular adverse effects</P>
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Antimicrobials</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Doxycycline</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Downregulate the actions of matrix metalloproteinases, enzymes involved in the breakdown of collagen and which play a key role in the inflammatory and destructive processes of periodontitis (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Tinidazole</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Tetracycline</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Clofazimine</P>
</TD>
<TD VALIGN="TOP">
<P>Antimycobacterial</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dapsone</P>
</TD>
<TD VALIGN="TOP">
<P>Antimycobacterial</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Vitamins/Minerals</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Zinc sulphate</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Vitamin B12</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Vitamin B12, a water-soluble vitamin, occurs in the body mainly as methylcobalamin (mecobalamin) and as adenosylcobalamin (cobamamide) and hydroxocobalamin. Mecobalamin and cobamamide act as coenzymes in nucleic acid synthesis (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>Herbal/Complementary</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Perilla oil</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>See Natural Medicines Comprehensive Database monograph (<LINK REF="REF-NMCD-2012" TYPE="REFERENCE">NMCD 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Soybean oil</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LongoVital</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Camel Thorn</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Beta-glucan</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>See Natural Medicines Comprehensive Database monograph (<LINK REF="REF-NMCD-2012" TYPE="REFERENCE">NMCD 2012</LINK>).</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Bee-propolis</P>
</TD>
<TD VALIGN="TOP">
<P>Antibacterial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Miscellaneous</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Colchicine</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Colchicine produces a dramatic response in acute gout, probably by reducing the inflammatory reaction to urate crystals; this effect might be due to several actions including decreased lactic acid production by leucocytes. Colchicine also appears to inhibit &#946;-tubulin polymerisation, inhibiting the activation, degranulation and migration of neutrophils, which may mediate some gout symptoms (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sodium cromoglyctae</P>
</TD>
<TD VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD VALIGN="TOP">
<P>Stabilisation of mast cell membranes &#8211; decreasing release of inflammatory mediators (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Levamisole</P>
</TD>
<TD VALIGN="TOP">
<P>Immunostimulant</P>
</TD>
<TD VALIGN="TOP">
<P>Modulates cell-mediated immune response (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Montelukast</P>
</TD>
<TD VALIGN="TOP">
<P>Leukotriene receptor antagonist</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pentoxifylline</P>
</TD>
<TD VALIGN="TOP">
<P>Vasodilator</P>
</TD>
<TD VALIGN="TOP">
<P>Inhibits production of the cytokine TNF&#945; (<LINK REF="REF-Martindale-2012" TYPE="REFERENCE">Martindale 2012</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sulodexide</P>
</TD>
<TD VALIGN="TOP">
<P>Antithrombotic</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Thalidomide</P>
</TD>
<TD VALIGN="TOP">
<P>Immunomodulator</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Table provided by Lindsay Banks, North West Medicines Information Centre, May 2012</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-08-13 10:38:15 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-08-13 10:38:15 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intervention versus control</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-13 10:36:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Recurrence</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-13 10:36:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Colchicine versus prednisolone</NAME>
<DICH_DATA CI_END="1.7115925885286822" CI_START="0.9817663964273096" EFFECT_SIZE="1.2962962962962963" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.2334003972509785" LOG_CI_START="-0.007991836868401865" LOG_EFFECT_SIZE="0.11270428019128832" MODIFIED="2012-04-02 22:47:06 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.14179499323255423" STUDY_ID="STD-Pakfetrat-2010" TOTAL_1="17" TOTAL_2="17" VAR="0.0201058201058201" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-08-03 14:29:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="167" TOTAL_2="165" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Episode duration (days)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2012-05-09 10:15:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin B12 versus placebo</NAME>
<CONT_DATA CI_END="-0.3301731904209886" CI_START="-5.389826809579011" EFFECT_SIZE="-2.86" ESTIMABLE="YES" MEAN_1="1.98" MEAN_2="4.84" MODIFIED="2012-04-13 11:57:22 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="3.77" SD_2="5.71" SE="1.2907516819359754" STUDY_ID="STD-Volkov-2009" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" MODIFIED="2012-07-04 11:42:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Montelukast versus placebo</NAME>
<CONT_DATA CI_END="-3.5212200807425544" CI_START="-4.378779919257444" EFFECT_SIZE="-3.9499999999999993" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="10.85" MODIFIED="2012-05-09 10:15:52 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="0.64" SD_2="0.74" SE="0.21876928486421487" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.03" MODIFIED="2012-07-04 11:43:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone versus placebo</NAME>
<CONT_DATA CI_END="-5.956125255349201" CI_START="-6.743874744650799" EFFECT_SIZE="-6.35" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="10.85" MODIFIED="2012-05-09 10:17:09 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.51" SD_2="0.74" SE="0.20096019506359958" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.04" MODIFIED="2012-07-04 11:43:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone versus montelukast</NAME>
<CONT_DATA CI_END="-2.0413480118402485" CI_START="-2.758651988159752" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="6.9" MODIFIED="2012-05-09 10:18:56 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="0.51" SD_2="0.64" SE="0.18298907071188705" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.05" MODIFIED="2012-07-04 11:43:25 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Perilla versus soybean</NAME>
<CONT_DATA CI_END="3.4300545336164725" CI_START="-1.830054533616471" EFFECT_SIZE="0.8000000000000007" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="6.6" MODIFIED="2012-05-09 11:47:56 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="4.5" SD_2="2.6" SE="1.3418892154968185" STUDY_ID="STD-Hamazaki-2006" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.06" MODIFIED="2012-07-02 13:44:23 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Multivitamin versus placebo</NAME>
<CONT_DATA CI_END="1.4003269071394762" CI_START="-2.0603269071394763" EFFECT_SIZE="-0.33000000000000007" ESTIMABLE="YES" MEAN_1="8.66" MEAN_2="8.99" MODIFIED="2012-07-02 13:44:23 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SD_1="4.6" SD_2="5.22" SE="0.8828360729013768" STUDY_ID="STD-Lalla-2012" TOTAL_1="61" TOTAL_2="63" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2012-08-03 14:29:54 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="168" TOTAL_2="162" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of new lesions</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2012-07-02 13:41:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="83" TOTAL_2="77" WEIGHT="0.0" Z="0.0">
<NAME>Multivitamin versus placebo</NAME>
<CONT_DATA CI_END="1.0344213259024302" CI_START="-1.8544213259024287" EFFECT_SIZE="-0.40999999999999925" ESTIMABLE="YES" MEAN_1="4.19" MEAN_2="4.6" MODIFIED="2012-07-02 13:41:11 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="4.74" SD_2="4.58" SE="0.7369631979443707" STUDY_ID="STD-Lalla-2012" TOTAL_1="83" TOTAL_2="77" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" MODIFIED="2012-07-04 11:43:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Montelukast versus placebo</NAME>
<CONT_DATA CI_END="-3.2484777826607134" CI_START="-4.551522217339287" EFFECT_SIZE="-3.9000000000000004" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="8.4" MODIFIED="2012-05-09 10:31:23 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="1.0" SD_2="1.1" SE="0.33241540277189324" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.03" MODIFIED="2012-07-04 11:44:17 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone versus placebo</NAME>
<CONT_DATA CI_END="-3.5630117050244827" CI_START="-4.836988294975518" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="8.4" MODIFIED="2012-05-09 10:31:40 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="0.95" SD_2="1.1" SE="0.325" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.04" MODIFIED="2012-07-04 11:44:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Prednisone versus montelukast</NAME>
<CONT_DATA CI_END="0.30449877611003395" CI_START="-0.9044987761100336" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.5" MODIFIED="2012-05-09 10:31:58 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="0.95" SD_2="1.0" SE="0.3084234102658227" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.05" MODIFIED="2012-07-02 16:27:53 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>SDD versus placebo</NAME>
<CONT_DATA CI_END="-2.3648513162628024" CI_START="-30.435148683737197" EFFECT_SIZE="-16.4" ESTIMABLE="YES" MEAN_1="16.0" MEAN_2="32.4" MODIFIED="2012-07-02 16:27:53 +0100" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="12.9" SD_2="33.4" SE="7.1609217283810604" STUDY_ID="STD-Preshaw-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2012-08-13 10:36:47 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of new lesions per day</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2012-08-13 10:36:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>SDD versus placebo</NAME>
<CONT_DATA CI_END="-0.033497151972413736" CI_START="-0.34650284802758624" EFFECT_SIZE="-0.18999999999999997" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.36" MODIFIED="2012-04-02 22:22:59 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="0.15" SD_2="0.37" SE="0.07984985911070852" STUDY_ID="STD-Preshaw-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2012-08-13 10:37:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="11" TOTAL_2="14" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of new lesions per week</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2012-08-13 10:37:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Tetracycline versus placebo</NAME>
<CONT_DATA CI_END="0.40081223522648046" CI_START="-1.3408122352264806" EFFECT_SIZE="-0.4700000000000001" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="1.33" MODIFIED="2012-07-02 17:24:54 +0100" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="0.4" SD_2="1.6" SE="0.4443001208671875" STUDY_ID="STD-Graykowski-1978" TOTAL_1="11" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2012-08-09 16:26:38 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of new lesions per month (6 month tx)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2012-08-09 16:26:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>LongoVital herbal alone</NAME>
<CONT_DATA CI_END="1.6956019589197373" CI_START="-3.295601958919737" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="4.8" MODIFIED="2012-05-08 14:22:21 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="4.6" SD_2="4.3" SE="1.2732897025683771" STUDY_ID="STD-Bratel-2005" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-03 14:30:22 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="28" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Levamisole versus placebo</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-03 14:00:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Decrease in frequency of attacks</NAME>
<DICH_DATA CI_END="25.38676639880631" CI_START="0.7235008448984329" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4046073867898767" LOG_CI_START="-0.14056095737906546" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2012-07-02 14:02:04 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.9076395340714969" STUDY_ID="STD-Van-de-Heyning-1978" TOTAL_1="7" TOTAL_2="5" VAR="0.823809523809524" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-03 14:03:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Decrease in duration of attacks</NAME>
<DICH_DATA CI_END="27.243314403378925" CI_START="0.6741964897082218" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.43525994243072" LOG_CI_START="-0.1712135130199088" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2012-08-03 14:03:30 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.9436504599035548" STUDY_ID="STD-Van-de-Heyning-1978" TOTAL_1="7" TOTAL_2="6" VAR="0.8904761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-03 14:04:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Decrease in number of ulcers</NAME>
<DICH_DATA CI_END="121.96029635381628" CI_START="0.5084902780171004" EFFECT_SIZE="7.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0862184709956613" LOG_CI_START="-0.29371734607238503" LOG_EFFECT_SIZE="0.8962505624616381" MODIFIED="2012-08-03 14:04:45 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.3979860798180643" STUDY_ID="STD-Van-de-Heyning-1978" TOTAL_1="7" TOTAL_2="6" VAR="1.9543650793650795" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-08-03 14:06:06 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="0.0" Z="0.0">
<NAME>Decrease in pain</NAME>
<DICH_DATA CI_END="27.243314403378925" CI_START="0.6741964897082218" EFFECT_SIZE="4.285714285714286" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.43525994243072" LOG_CI_START="-0.1712135130199088" LOG_EFFECT_SIZE="0.6320232147054056" MODIFIED="2012-08-03 14:06:06 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.9436504599035548" STUDY_ID="STD-Van-de-Heyning-1978" TOTAL_1="7" TOTAL_2="6" VAR="0.8904761904761905" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-08-03 14:30:28 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="27" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of episodes per month</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2012-08-03 11:53:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin B12 versus placebo</NAME>
<CONT_DATA CI_END="-0.8627526645186174" CI_START="-16.617247335481384" EFFECT_SIZE="-8.74" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="14.74" MODIFIED="2012-04-13 12:04:53 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="11.79" SD_2="17.75" SE="4.019077594086475" STUDY_ID="STD-Volkov-2009" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="83" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-08-10 12:21:45 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="111" TOTAL_2="107" WEIGHT="0.0" Z="0.0">
<NAME>Ulcer-free status</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-02 13:56:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin B12 versus placebo</NAME>
<DICH_DATA CI_END="8.657467502978205" CI_START="1.2321846835335282" EFFECT_SIZE="3.2661290322580645" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="0.9373908700391442" LOG_CI_START="0.0906758060657229" LOG_EFFECT_SIZE="0.5140333380524335" MODIFIED="2012-04-13 12:09:26 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.49736461988515085" STUDY_ID="STD-Volkov-2009" TOTAL_1="31" TOTAL_2="27" VAR="0.2473715651135006" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="28" EVENTS_2="24" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-02 13:56:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Rofexib versus tinidazole</NAME>
<DICH_DATA CI_END="1.4290733486968317" CI_START="0.952443142510708" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.15505451998535844" LOG_CI_START="-0.021160940724132007" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2012-07-02 13:56:22 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.10350983390135315" STUDY_ID="STD-Lu-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.010714285714285718" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="40" EVENTS_2="20" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-02 13:56:25 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Homeopathy versus placebo</NAME>
<DICH_DATA CI_END="2.8858597618059902" CI_START="1.3860687386613595" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="20" LOG_CI_END="0.4602752227541434" LOG_CI_START="0.14178476857381903" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2012-07-02 13:56:25 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.18708286933869708" STUDY_ID="STD-Mousavi-2009" TOTAL_1="50" TOTAL_2="50" VAR="0.035" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2012-08-09 16:26:58 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of days of pain per month (6 month tx)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2012-08-09 16:26:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>LongoVital herbal alone</NAME>
<CONT_DATA CI_END="1.792690059989952" CI_START="-9.392690059989953" EFFECT_SIZE="-3.8000000000000007" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="16.5" MODIFIED="2012-05-08 14:27:27 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="8.0" SD_2="11.7" SE="2.853465729015624" STUDY_ID="STD-Bratel-2005" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2012-08-09 16:27:40 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="23" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean size of aphthae per month (6 month tx)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" MODIFIED="2012-08-09 16:27:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>LongoVital herbal alone</NAME>
<CONT_DATA CI_END="-0.038316643674858375" CI_START="-0.5616833563251413" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.3" MODIFIED="2012-05-08 14:30:09 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="0.4" SD_2="0.5" SE="0.1335143698502964" STUDY_ID="STD-Bratel-2005" TOTAL_1="23" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2012-08-09 16:28:02 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>General discomfort per month (6 month tx)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.01" MODIFIED="2012-08-09 16:28:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>LongoVital herbal alone</NAME>
<CONT_DATA CI_END="0.9721276346897437" CI_START="-0.3721276346897432" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="3.3" MODIFIED="2012-05-08 14:31:31 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="1.2" SD_2="1.2" SE="0.34292856398964494" STUDY_ID="STD-Bratel-2005" TOTAL_1="24" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2012-08-03 14:31:19 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of ulcers at completion</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.01" MODIFIED="2012-08-03 14:16:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Colchicine versus prednisolone</NAME>
<CONT_DATA CI_END="0.23528646563709435" CI_START="-0.49528646563709433" EFFECT_SIZE="-0.12999999999999998" ESTIMABLE="YES" MEAN_1="0.23" MEAN_2="0.36" MODIFIED="2012-05-09 12:20:47 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="0.44" SD_2="0.63" SE="0.1863740704004907" STUDY_ID="STD-Pakfetrat-2010" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.02" MODIFIED="2012-08-03 14:16:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Subantimicrobial dose doxycycline versus placebo</NAME>
<CONT_DATA CI_END="0.09835103583823812" CI_START="-1.0983510358382382" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.2" MODIFIED="2012-08-03 14:16:35 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="0.8" SD_2="1.3" SE="0.30528675044947495" STUDY_ID="STD-Preshaw-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2012-08-13 10:38:15 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="154" TOTAL_2="152" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain (VAS)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.01" MODIFIED="2012-08-13 10:38:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>SDD versus placebo</NAME>
<CONT_DATA CI_END="1.931182006815341" CI_START="-11.931182006815341" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="10.4" MEAN_2="15.4" MODIFIED="2012-04-02 22:28:06 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="9.2" SD_2="15.1" SE="3.536382332271215" STUDY_ID="STD-Preshaw-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.02" MODIFIED="2012-08-09 16:30:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Colchicine versus prednisolone</NAME>
<CONT_DATA CI_END="0.8553160950864341" CI_START="-1.1753160950864343" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="0.93" MODIFIED="2012-04-02 22:50:46 +0100" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="1.48" SD_2="1.54" SE="0.5180279347452902" STUDY_ID="STD-Pakfetrat-2010" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.03" MODIFIED="2012-04-13 11:52:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>Vitamin B12 versus placebo</NAME>
<CONT_DATA CI_END="-0.7425394657201562" CI_START="-2.6974605342798434" EFFECT_SIZE="-1.7199999999999998" ESTIMABLE="YES" MEAN_1="0.64" MEAN_2="2.36" MODIFIED="2012-04-13 11:52:14 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="1.45" SD_2="2.21" SE="0.49871351820233817" STUDY_ID="STD-Volkov-2009" TOTAL_1="31" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.04" MODIFIED="2012-08-13 10:38:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Montelukast versus placebo</NAME>
<CONT_DATA CI_END="-0.8369881676009611" CI_START="-1.463011832399038" EFFECT_SIZE="-1.1499999999999995" ESTIMABLE="YES" MEAN_1="3.45" MEAN_2="4.6" MODIFIED="2012-05-16 11:15:34 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="0.51" SD_2="0.5" SE="0.15970284906663376" STUDY_ID="STD-Femiano-2010" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.05" MODIFIED="2012-07-02 13:51:11 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Multivitamin versus placebo</NAME>
<CONT_DATA CI_END="0.6102295186486455" CI_START="-0.710229518648646" EFFECT_SIZE="-0.050000000000000266" ESTIMABLE="YES" MEAN_1="2.07" MEAN_2="2.12" MODIFIED="2012-07-02 13:51:11 +0100" MODIFIED_BY="[Empty name]" ORDER="27" SD_1="1.89" SD_2="1.86" SE="0.3368579850734258" STUDY_ID="STD-Lalla-2012" TOTAL_1="61" TOTAL_2="63" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-08-13 10:52:23 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-08-13 10:52:23 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWAAAARDCAIAAADZA2wkAAA690lEQVR42u3dvW4lxfr2YUskBA4m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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-08-09 10:11:06 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAKTCAYAAAA3w17/AAAeKklEQVR42u3d4bKjOA5A4X7/l579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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-08-13 10:55:49 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-07-02 15:15:32 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-08-22 14:36:54 +0100" MODIFIED_BY="[Empty name]">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-02 15:15:32 +0100" MODIFIED_BY="[Empty name]">
<P>1.             Stomatitis, aphthous/                                    <BR/>2.             (recur$ or reoccur$ or severe).ti,ab.                                    <BR/>3.             1 and 2                                    <BR/>4.             ((recur$ or reoccur$ or severe) adj10 ((aphthous or apthous or mouth$ or oral$) adj3 (ulcer$ or lesion$ or stomatitis))).ti,ab.                                    <BR/>5.             (aphthae or aphthae).ti,ab.                                    <BR/>6.             "canker sore$".ti,ab.                                    <BR/>7.             "herpetiform ulcer$".ti,ab.                                    <BR/>8.             "periadenitis mucosa necrotica recurrens".ti,ab.                                    <BR/>9.             or/3-8</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-11-17 15:19:33 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-11-17 15:16:23 +0000" MODIFIED_BY="[Empty name]">Review eligibility form</TITLE>
<APPENDIX_BODY MODIFIED="2011-11-17 15:19:33 +0000" MODIFIED_BY="[Empty name]">
<P>Author name&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.           </P>
<P>Journal&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.&#8230;&#8230;&#8230;&#8230;&#8230;.         </P>
<P>Year&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</P>
<TABLE COLS="5" ROWS="8">
<TR>
<TD VALIGN="TOP">
<P>
<B>Criteria</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>1. Is the study a RCT?        </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2. Does the study include a systemic intervention for the prevention, palliative care or treatment of RAS? </B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD COLSPAN="5" VALIGN="TOP">
<P>If NO, does it include a topical or physical intervention for the prevention, palliative care or treatment of RAS?</P>
<P>                                                                                                                                                                                               </P>
<P>Topical     Yes/No</P>
<P>Physical    Yes/No</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>3. Does the study exclude patients who have ulceration secondary to a medical condition/systemic disease?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>4. Is the study restricted to adults?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Is the study eligible (meets criteria 1-4)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Points for clarification with the author</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P> </P>
<P> </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-08-13 10:55:49 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-11-17 15:20:45 +0000" MODIFIED_BY="[Empty name]">Risk of bias and data extraction form</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-13 10:55:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Risk of bias in methodology</B>
</I>
</P>
<TABLE COLS="5" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study design</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Parallel / cross-over</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Power calc<SUP>n</SUP>
</B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B>Yes / no / unclear</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Sequence generation</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as:</P>
<P>·       random number table;</P>
<P>·       using a computer random number generator;</P>
<P>·       coin tossing;</P>
<P>·       shuffling cards or envelopes;</P>
<P>·       throwing dice;</P>
<P>·       drawing of lots;</P>
<P>·       minimization</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process:</P>
<P>·       sequence generated by odd or even date of birth;</P>
<P>·       sequence generated by some rule based on date (or day) of admission;</P>
<P>·       sequence generated by some rule based on hospital or clinic record number;</P>
<P>·       allocation by judgement of the clinician;</P>
<P>·       allocation by preference of the participant;</P>
<P>·       allocation based on the results of a laboratory test or a series of tests;</P>
<P>·       allocation by availability of the intervention.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation:</P>
<P>·       Central allocation (including telephone, web-based and pharmacy-controlled randomization);</P>
<P>·       Sequentially numbered drug containers of identical appearance;</P>
<P>·        Sequentially numbered, opaque, sealed envelopes.</P>
</TD>
<TD VALIGN="TOP">
<P>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:</P>
<P>·       Using an open random allocation schedule (e.g. a list of random numbers);</P>
<P>·       Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered);</P>
<P>·       Alternation or rotation;</P>
<P>·       Date of birth;</P>
<P>·       Case record number;</P>
<P>·       Any other explicitly unconcealed procedure.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Blinding of participants, personnel and outcome assessors</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<P>·       No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding;</P>
<P>·       Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken;</P>
<P>·       Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<P>·       No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding;</P>
<P>·       Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;</P>
<P>·       Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<P> </P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<P>·        No missing outcome data;</P>
<P>·        Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</P>
<P>·        Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</P>
<P>·        For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</P>
<P>·        For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</P>
<P>·        Missing data have been imputed using appropriate methods.</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<P>·        Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</P>
<P>·        For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</P>
<P>·        For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</P>
<P>·        &#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomization;</P>
<P>·        Potentially inappropriate application of simple imputation.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Selective outcome reporting </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Any of the following:</P>
<P>·        The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;</P>
<P>·        The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<P>·        Not all of the study&#8217;s pre-specified primary outcomes have been reported;</P>
<P>·        One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;</P>
<P>·        One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);</P>
<P>·        One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;</P>
<P>·        The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Yes (low risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>No (high risk of bias)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Unclear</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Score</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Other potential threats to validity</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>The study appears to be free of other sources of bias.</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>There is at least one important risk of bias. For example, the study:</P>
<P>·        Had a potential source of bias related to the specific study design used; or</P>
<P>·        Stopped early due to some data-dependent process (including a formal-stopping rule); or</P>
<P>·        Had extreme baseline imbalance; or</P>
<P>·        Has been claimed to have been fraudulent; or</P>
<P>·        Had some other problem.</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to make judgement</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>y/n/u</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD COLSPAN="4" VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>
<B>Points for clarification with author:</B>
</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
<I>
<B>
<BR/>
</B>
</I>
</P>
<P>
<I>
<B> </B>
</I>
</P>
<P>
<I>
<B>Characteristics of included studies</B>
</I>
</P>
<TABLE COLS="2" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>Methods</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Location of Trial:</P>
<P> </P>
<P> </P>
<P>Number of Centres:</P>
<P> </P>
<P>Funding:</P>
<P> </P>
<P>Trial ID:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Participants</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Source of recruitment:</P>
<P> </P>
<P>Age:</P>
<P> </P>
<P>Gender:</P>
<P> </P>
<P>Inclusion Criteria:</P>
<P> </P>
<P>Exclusion Criteria:</P>
<P> </P>
<P>Number randomised:</P>
<P> </P>
<P>Number analysed:</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Interventions</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Comparison:</P>
<P>Gr A (n= )</P>
<P>Gr B (n= )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcomes</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Primary:</P>
<P>Secondary:</P>
<P>Duration of follow-up:</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Notes</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<P>
<I>
<B>
<BR/>
</B>
</I>
</P>
<P>
<I>
<B>Outcomes assessed</B>
</I>
</P>
<P>
<B>Primary outcomes</B>
</P>
<P>Was a reduction of pain associated with recurrent aphthous stomatitis reported?                                  Yes                 No                   Unclear</P>
<P> </P>
<P>Was a reduction in episode duration associated with recurrent aphthous stomatitis?                           Yes                 No                   Unclear</P>
<P> </P>
<P>Was a reduction in episode frequency associated with recurrent aphthous stomatitis?                         Yes                 No                   Unclear</P>
<P> </P>
<P>Were adverse events reported?               Yes                 No                   Unclear</P>
<P> </P>
<P>
<B>Secondary outcomes</B>
</P>
<P>Was a reduction in morbidity reported? Yes                 No                   Unclear</P>
<P> </P>
<P>Was quality of life considered?                Yes                 No                   Unclear</P>
<P> </P>
<P>Were costs issues considered?              Yes                 No                   Unclear</P>
<P> </P>
<P> </P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD VALIGN="TOP">
<P>
<B>Additional comments/outcomes measured</B>
</P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
<P> </P>
</TD>
</TR>
</TABLE>
<P>
<I>
<B> </B>
</I>
</P>
<P>
<I>
<B>
<BR/>
</B>
</I>
</P>
<P>
<I>
<B>Results</B>
</I>
</P>
<P>
<B>Table 1. Summary of dichotomous data for primary outcomes</B>
</P>
<P>
<B> </B>
</P>
<TABLE COLS="5" ROWS="5">
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Source of data (e.g. figure, text, table)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp1</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>n/N</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp2</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>n/N</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B>
<BR/>
</B>
</P>
<P>
<B>Table 2 Summary of data for secondary outcomes</B>
</P>
<P>
<B> </B>
</P>
<P>Dichotomous data</P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Source of data (e.g. figure, text, table)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp1</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>n/N</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp2</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>n/N</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P>
<B> </B>
</P>
<P>Continuous data</P>
<TABLE COLS="5" ROWS="3">
<TR>
<TD VALIGN="TOP">
<P>
<B>Outcome </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Source of data (e.g. figure, text, table)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp1</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>N</B>
</P>
<P>
<B>Mean(sd)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Gp2</B>
</P>
<P>
<B>&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;</B>
</P>
<P>
<B>N</B>
</P>
<P>
<B>Mean(sd) </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Comments</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
</TABLE>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-03-27 10:17:38 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 studies included in the review&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;86 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1289 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1289 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;1940 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1203 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;61 full-text articles excluded due to: a) inclusion in topical interventions review; b) abstract only; c) inappropriate washout; d) not RCT&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>